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Abstract 
Contrast agents allow for greater detail of specific internal 
structures to be obtained under clinical MR imaging. These images are 
used to aid in the diagnosis of conditions or damage including tumours 
and other cancerous tissues. Gadolinium has for quite a while been used 
as a primary material for this purpose but increasing concerns regarding 
toxicity are adding pressure to seek alternate materials. Magnetite offers 
many properties that would make it an excellent contrast material and 
several products have come to market but are restricted in their 
application primarily due to particle size.  
This thesis aims to approach the problems associated with 
magnetite nanoparticles and their use in intravenous systems. This 
requires reducing the overall particle size and ensuring biocompatibility. 
This was accomplished by modifying the core particle size by altering the 
thermal decomposition parameters and surface coating the material with 
a layer of silica. A preliminary investigation was made using quasi cubic 
magnetite particles to investigate the biocompatibility and performance as 
an MR contrast agent. Based on these findings a second core shell 
nanoparticle system was formed using modified techniques to reduce the 
overall particle size by shrinking the core magnetite and the silica shell 
thickness.  
These particles were subsequently surface modified with Herceptin® 
to facilitate the selective uptake of the particles into specific cancerous 
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cells. The particles were examined for their biocompatibility, structural 
stability and selective uptake into SKBR3 cells in vitro and in vivo in live 
breast tumour baring mice. All the studies were undertaken in MRI 
scanners in use by clinicians at the Peter MacCallum Cancer Research 
Centre. This demonstrated that in a clinical setting, these core shell 
particles can be made to selectively target specific tumours in significant 
number to cause notable localised contrast at the target site. 
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Chapter 1 
1.1.0 Introduction 
This chapter will serve to introduce the concepts of nanotechnology 
and its various applications with a focus on medical imaging techniques. 
The literature presented in this chapter should serve as a basis to justify 
the research conducted in the subsequent chapters and highlight the 
areas of the field that are lacking and require attention. 
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1.1.1 Nanotechnology 
Over time, humans as a species have developed ways to manipulate 
our environment to suit our needs. This has been possible due to certain 
physiological adaptations as well as a seemingly uncontrollable curiosity 
that has driven us to develop technologies to enhance our lives. The 
development of the ―pointed stick‖ would likely have been among the first 
technological developments sought by our ancestors, but even this 
simplistic concept requires understanding of the principles and materials 
involved. Our ancestors more than likely had experiences in life where 
they learned that pointy things were more unpleasant to be poked with 
than blunt things (experience). They would have realised that having a 
good pointy stick around was beneficial to their survival and set about 
collecting pointy sticks for this purpose (requirement). Arguably the best 
pointy sticks were long, straight and rigid; sticks such as this would have 
been hard to find (value in attributes). However with a little understanding 
of the materials and the desired application, a premium pointed stick 
could be crafted from a non-premium material (creative solution).  
This process of fulfilling a need by first increasing our 
understanding of the world, then applying this new knowledge in creative 
ways, is the core of the technological development cycle. It is also the only 
reason these clawless, unarmoured and quite tasty humans have survived 
to this day. This cycle has allowed us to reach a point in our history when 
we have the opportunity to develop tools on a scale that may one day 
allow us to control the very atomic structures of materials. As we enter 
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this era of ―Nanotechnology‖ we seek to further develop the tools and 
understanding of this world below us, in order to create new and 
important tools to solve the problems we face as a species. 
Nanotechnology refers broadly to all fields of science that seek to 
control at least one dimension of a material structure on the nanoscale, in 
order to alter its properties or application. This includes physics, 
chemistry, electronics, biology and materials engineering, making it a 
truly multidisciplinary field. The term ―nanotechnology‖ comes from the 
coupling of the Greek prefix ―Nano‖, meaning ―Dwarf‖ and of course the 
word ―technology‖; this size prefix denotes a fraction of one billionth 
(1/1,000,000,000th). In the case of the unit of length, one ―nanometre‖ is 
equal to a billionth of a metre (0.000000001 m). However the term 
nanotechnology is generally used to refer to any material that has one 
aspect of its structure controlled on the scale of less than 100 nm. It is 
often difficult to put this size range into perspective as it is far below the 
common units that humans interact with in everyday life. Figure 1 below 
is a simplified diagram used to describe the relationship this size range 
has to our everyday world, from the diagram we can already see manmade 
developments at and below this scale. Yet we still lack the understanding 
required to equal or even come close to the complexities of the biological 
world, which for the time being remain the only true nanomachines.  
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Figure 1: Scale diagram representing the relative sizes of man-made and biological 
nanostructures, image courtesy of Josh Wolfe's report on nanotechnology: 
[http://www.forbeswolfe.com] 
 
Richard Feynman worked tirelessly in the field of quantum 
mechanics and to this day, his efforts remain as the cornerstones of 
modern physics. Yet it was a semi off the cuff after dinner talk given by 
him in 1959 entitled ―There’s plenty of room at the bottom‖ that began 
courses of inquiry and serious idle conversation into the realms of 
―Nanotechnology‖. In the talk he discussed reaching the limits and 
physical boundaries of atomic scale fabrication and proposed shrinking 
computer components down until internal connects were made of wires 
―10-100 atoms in diameter‖.  
When Feynman gave his talk, computers still took up whole rooms; 
however now we are beginning to reach his milestones with interconnects 
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now being made at less than 30 nm which is equivalent to Feynman’s 100 
atom upper limit. What Feynman envisioned was the fabrication of devices 
on an ever decreasing scale, until we are able to directly manipulate each 
atom of a material so we can arrange them any way we want. This 
approach, making ever smaller devices and components from larger 
materials, is referred to as the ―top down‖ method and is used extensively 
in the lithographic processes to make computer chips. However, since he 
gave his talk there have been discoveries in biology of machines that 
already operate at this scale. Biology has become recognised as a field full 
of nanotechnology, where incredibly complex systems and machines are 
fabricated by molecular sized pumps and engines that researchers are 
beginning to understand and reprogram [1-4]. The method used by 
biology, by which it forms larger much more complex structures using 
small building blocks, is termed the ―bottom up‖ approach.  
The simplest advantage nanomaterials have is that of surface area, 
a solid 1 cm3 block has a surface area of 6 cm2, if this block is subdivided 
into 1 mm cubes; the same volume now has a surface area of 60 cm2. If 
you divide further into the nanoscale and make that same 1 cm3 block out 
of 1 nm cubes, the available surface area of that volume climbs to 
60,000,000 cm2 (Figure 2). This dramatic change in surface area to 
volume ratio can affect many aspects of a material properties including 
chemical reactivity [5], electrical conductivity [6-8], magnetic properties 
[9], strength, ductility and melting temperature [10-12]. Certain 
phenomena also begin to manifest in nanomaterials that are not observed 
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in the bulk such as quantum confinement and surface plasmon 
resonance [5, 9]. These features make investigating nanomaterials a high 
priority for just about every major industry and scientific field. The fruits 
of these early investigations have already begun to be born and more than 
just hints of interesting materials and their properties have been 
uncovered. 
 
 
Figure 2: Comparison of surface area increase with reduction in unit size increasing 
surface area. Image courtesy of the United States National Nanotechnology Initiative [13] 
 
Carbon nanotubes (CNT’s) for example have many useful properties 
such as high tensile strength and flexibility [14, 15], electrical properties 
[16-19] and hydrophobicity [20-22] which can be applied to many fields. 
For example, the semiconductor industry has been steadily improving the 
number of transistors that can be fabricated onto a single photo 
lithographically printed chip; approximately adhering to Moore’s law of a 
doubling of computer power every 2 years. However, it has been accepted 
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that the current methods of fabrication will hit limitations in minimum 
feature size once 22 nm feature sizes are obtained. This is not due to 
simple fabrication restrictions, which although technically difficult, sub 
22 nm features can be obtained; but due to quantum tunnelling, short 
channel effects and passive power dissipation occurring as a consequence 
of how the materials begin to behave on this scale [23, 24]. The 
exceptional electrical properties of CNT’s have been extensively 
investigated in attempts to overcome this problem. Bundles of, or single 
CNT’s can be used to replace the channel material used in a transistor, 
because CNT’s have strong covalent C-C bonding in the sp2 region, they 
remain chemically inert yet capable of conducting large amounts of 
electrical charge ballisticly down their quasi 1D structure [25-27]. Their 
properties can be tuned by altering the chirality of the tubes [28, 29], 
surface or terminal coatings [30, 31], for use in solar cells [32-34], 
conductive films [35, 36], textiles [37, 38], oscillators [39, 40] and even 
massive scale applications such as creating a space elevator using CNT’s 
to construct the cables [41]. ―The space elevator will be made about 50 
years after everyone stops laughing‖ Arthur C. Clark. As such, CNT’s are 
demonstrating wide reaching applications with very little change in their 
structure demonstrating the multifunctionality of a single tool produced 
by nanoscience.  
For many years, biologists have been working with nanotechnology; 
all primary biological systems operate on the nanoscale to some degree. 
But it is only in the last few decades the functionality of the pumps and 
20 
 
motors that operate at the molecular scale have begun to be understood. 
These molecular machines are still out of our power to produce yet every 
year more and more is understood about their functioning. However 
researchers have been able to begin exploiting bio mimicry and 
reappropriation of naturally occurring nanomachines for other purposes, 
such as protein kinesin being used as a ―linear walker‖ after extraction 
and adhesion to a track surface with a supply of ATP to drive the required 
conformational changes [42, 43]. 
Motors that spin the flagella on bacteria, proton pumps that 
selectively pump ions across membranes, the functioning of ribosomes as 
they transcribe RNA into proteins, are all demonstrations of true 
nanomachines. They demonstrate exquisite precision in their function and 
operate with extreme efficiency. Only recently have researchers been able 
to begin to fabricate structures on the same scale and although we are 
beginning to realise some of the benefits of nano engineered materials in 
biology, we are still a long way from designing our own motors, pumps 
and protein folders. However we have begun to develop understanding of 
how material properties change once particular attributes such as size 
and shape are constricted on the nano scale. 
 
1.1.2 Scale matters and matter is scalable  
Although much technological advancement has been made by 
reducing the size of components, computers being a prime example, mere 
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size reduction is only half the story. In order to fully appreciate the 
possibilities and potential of materials engineered on the nanoscale, an 
understanding of quantum effects is required. Quantum theory was 
developed as a means of describing the behaviour of matter as it departs 
from classical mechanics on the atomic and subatomic scale. Although 
defining quantum theory to a subset of behaviours, probabilities and 
properties of subatomic systems is well outside the realm of this thesis, 
one aspect ―Spin‖ will be discussed later in sections 1.3.2 & 1.4.1. 
However, what does need to be understood is that once a material is 
reduced in size to below certain limits, these effect can begin to manifest 
as useful properties that aren’t exhibited in the ―bulk‖ state. This change 
is due to the size range being comparable to the De Broglie wavelength of 
the charge carriers within the material. Various physical phenomena such 
as, conductance, melting point, fluorescence and magnetic permeability 
are directly linked to their charge carrier wavelength [44-48]. As such, 
once the particle size is reduced to less than that of the charge carrier 
wavelength, the wavelength begins to exist in a constricted state and 
whatever property that charge imparts can shift. This means that at this 
scale morphology becomes increasingly important and that by changing 
the particle size, shape, spacing and dielectric conditions, we can actively 
manipulate the properties of the material for our needs.  
One clear example of this change in properties in metal 
nanoparticles is the visible colour shift when the particle size confinement 
begins to affect the surface plasmon properties of the surface. Similar to 
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the ―particle in a box‖ principle, the oscillations in the coherent charge 
density at the interface between the metal and dielectric layer begin to 
blue-shift with decreasing size once below a critical size of about a few 
nanometers and is clearly observable with gold nanoparticles. This 
property of gold has been known for an exceptionally long time and lead to 
the use of gold particles in creating stained glass windows back as far as 
the 4th century AD [49, 50]. However it has only been recently that this 
property of gold has become understood and that the colour shift is 
caused by the surface plasmon of the material. Within metallic materials, 
the free electrons often depicted as a ―sea of free electrons‖, have a natural 
standing wave frequency of oscillation. However the electrons on the 
boundary between the edge of the material and either another material or 
vacuum, oscillate with a separate standing wave that runs parallel to the 
interface. When light interacts with the surface of a bulk metal, it typically 
undergoes elastic interaction with the electrons forming the metallic 
bonds and is reflected with only a very small portion being absorbed. This 
is the reason most metals in their pure form have a white lustre, as all 
frequencies are reflected from the surface.  
However if the relative permittivity of the material is such that the 
surface plasmon frequency is below that of the interacting light; the 
dielectric function of the free electrons transitions from negative 
(reflecting) to positive (transmitting). This results in there being an upper 
limit for the frequency of reflected light, in the case of gold and copper, 
this occurs within the visible light spectrum. The upper frequencies of the 
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incident light are transmitted and the reflected light spectrum is reduced, 
resulting in the gold and red colours of those metals. In bulk systems, the 
surface plasmon resonance is fixed, based on the atomic properties of the 
material. However in nanoparticle systems, the surface plasmon frequency 
is confined to the outer layer of the individual particle. Therefore, by 
reducing the particle diameter, the surface plasmon resonance can be 
―shifted‖ and different transmission spectra can be observed. In this way, 
the visible colour of a material can be ―tuned‖ simply by changing the 
particle size as demonstrated in Figure 3 below [51].  
 
 
Figure 3: How the physical properties of gold nanoparticles affect the observed colour 
with only change in particle size and shape. Sánchez-Iglesias, A., I. Pastoriza-Santos, et 
al. [51] 
 
Tuning material properties by nanoscale manipulation has allowed 
for nanomaterials to be applicable to a plethora of fields and applications. 
Such as semiconductors [52-55], medical diagnostics [52, 56-59], 
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biosensors [52, 58, 60, 61], information storage [62], single electron 
transistors [52, 63-65], solar cells [52, 66, 67], cell tracking [52, 68-71], 
energy storage [72-75], environmental protection [76] and smart surfaces 
[77-79], to name only a handful. It is difficult to appreciate how a single 
advancement can affect so many aspects of our lives but it is becoming 
much clearer to both the research and lay community that a great change 
in what we understand about the world has given rise to some very useful 
tools. 
 "Every industry that involves manufactured items will be impacted 
by nanotechnology research. Everything can be made in some way 
better—stronger, lighter, cheaper, easier to recycle—if it’s engineered and 
manufactured at the nanometre scale." -- Stan Williams, Director of 
Quantum Science Research, HP Labs.  
Although there are many aspects to consider in the field of 
nanomaterials; this thesis will focus one specific area, magnetic resonance 
imaging (MRI) contrast agents. The following sections will introduce the 
topic of MRI and how nanotechnology can play a part in its advancement.  
1.2.1 Nanotechnology and medicine 
Given the wide variety of nanoparticles and nanomaterial systems 
being researched, it is no surprise that much attention has been placed 
on medical applications given their broad material properties. 
Nanomaterials can positively benefit medical applications both passively 
and actively. Passive interaction is caused by a nanomaterials basic 
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properties being beneficial, such as the antimicrobial and anti-
inflammatory properties of silver nanoparticles [80-82]. As such, silver 
nanoparticles have found direct application areas such as treatment of 
minor cuts and grazes; burns and ulcers, and general wound healing that 
would otherwise require topical antiseptic treatment [83-85].  
Active nanoparticle applications take advantage of the size and 
surface modification of the materials to create specific structures that 
actively enhance the materials properties and application, such as hollow 
capsules for delivering drugs or other payloads [86]. Nanoparticles or 
capsules are typically 5-400 nm in diameter, which makes them small 
enough to behave as delivery systems for the much larger (≈10 µm) human 
cells. The ability to tailor materials on such an extreme scale allows us to 
begin to mimic the ways in which the human body has been working for 
hundreds of thousands of years. 
Our immune system uses a highly specific set of protein markers to 
identify healthy, infected, old or young cells. Now that researchers can 
manipulate materials on this scale, we can use the same system to target 
and transport therapeutics, toxins or signal molecules directly to specific 
cells or tissues increasing efficacy and decreasing side effects and toxicity 
[87]. Polymeric nanocapsules have found many applications in this area 
given their biocompatibility, controllable synthesis and ease of surface 
modification [88-91]. Poly (D,L-lactic-co-glycolic acid) (PLGA) particles 
have been used to deliver drugs such as antipsychotics, insulin, anti-
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inflammatories, chemotherapeutic and anti-cancer drugs to target tissues 
[92, 93]. 
Typically chemotherapy drug doses are more effective as they 
increase, however the highly toxic nature of chemotherapy drugs causes 
extensive systemic toxicity and side effects. Therefore dosage must be 
balanced between damage to tumour cells vs damage caused to healthy 
cells via the treatment. This often extends the period patients have to 
undergo therapy as the doses must be kept low, which increases 
likelihood of tumour cells becoming resistant to the chemotherapy drugs. 
However polymer capsules made from PLGA have demonstrated 
effectiveness in transporting chemotherapy agents such as 9-
nitrocamptotecin, cisplatin and paclitaxel directly to tumour sites which 
reduces the systemic toxicity of the drugs allowing for higher doses with 
reduced side effects, increasing efficacy [92, 93].  
Vaccine delivery is another area where polymer nanoparticles have 
found application. The same systems for drug delivery can be utilised for 
vaccines, by carrying the target surface proteins and stimulating the 
immune system to elicit the desired response. Polymer nanoparticles have 
demonstrated the ability to trigger both specific and non-specific immune 
responses to a desired target [94]. By stripping molecular markers from 
target cells and binding them to polymeric nanoparticles; researchers have 
been able to initiate an immune system response to cells that would 
otherwise escape the detection process [95].  
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The requirements of vaccine delivery are such that larger particles 
(sometimes greater than 1 µm) are required because they are readily taken 
into macrophages and dendritic cells where they can transmit their 
markers to the immune system for cataloguing [95, 96]. Smaller particles 
have also demonstrated effectiveness in providing immunogenicity [97, 
98]. Reddy et al. demonstrated that immunogenicity was increased when 
the particles were able to freely circulate in the lymphatic system for an 
extended period due to the decreased particles size. Once internalised into 
dendritic cells and macrophages, the target molecules can be transferred 
while the carrier particle is easily degraded [99-101]. The versatility of 
polymer nanoparticles makes them excellent vectors for vaccine delivery 
due to their controllable size, ease of surface coating and biodegradability. 
Vaccine and drug delivery systems take advantage of the molecular 
properties of nanomaterials to evade the reticuloendothelial system (RES), 
target specific cell types and deliver drugs. However these nano vectors 
can transport molecular probes to tissues that can aid in the formation of 
images for positron emission tomography (PET), computed tomography 
(CT) and magnetic resonance (MR) imaging by exploiting the physical 
properties of nanomaterials. This was originally suggested by Weissleder 
in 1999 when they deemed that the expanding understanding of 
molecular mechanisms of disease and their relevant biomarkers could be 
combined with advances in medical imaging [102]. Their group was even 
able to demonstrate this principle in the pre-clinical setting [103, 104]. 
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By combining molecular markers with nanoparticle probes, the 
spatial resolution was able to be increased for imaging modalities such as 
MR, CT and ultrasound (US). These techniques have a high spatial 
resolution and are typically used to diagnose disease prior to imaging with 
techniques such as PET or optical imaging, which although highly 
sensitive, possess low spatial resolution. It would be considered more 
effective if the more highly sensitive nuclear imaging techniques could be 
used routinely, however they fall short on several aspects. Exposure to the 
ionising radiation used to create the PET image causes damage to both 
patient cells and to the sensitive molecular probes being used. This limits 
the maximum exposure time and duration of biological processes that can 
be imaged. This greatly reduces usefulness for targeted molecular imaging 
as quite often longer scanning times may be required to deliver the probe 
to the target.  
For these reasons combined imaging modalities have been 
developed such as PET/CT and PET/MRI which have greatly enhanced 
performance compared to either technique individually. MRI demonstrates 
a higher spatial resolution than CT, hence PET/MRI produces the better 
combination and is under clinical development. For all these modalities, 
molecular markers and probes are required to produce high quality 
images. The continual development and implementation of nanomaterials 
for these applications remains an integral part of further improving 
imaging diagnostics.  
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1.2.2 Properties of materials 
Much like our stick wielding cousins, we can see how our experience 
that magnetic materials can offer advantages in the application of MR 
contrast; has driven our growing interest in the fundamentals of their 
design. Due to our advancements in imaging modalities, we now have a 
requirement to develop related technologies to improve that which we have 
already developed. From our collective research, we have ascertained 
many of the behaviours of magnetic particles at this scale. While 
attempting to apply this knowledge to MR contrast, we see specific value 
in several selected features. This allows us to produce a creative solution 
using the knowledge we have amassed about biology and the physical 
world, to fulfil the needs of the application. In this way we are still 
sharpening sticks, just to a much finer scale and the cycle of technological 
development rolls on unchanged. 
 
1.3.1 MRI contrast 
Nanofabrication advancements have led to the reliable production of 
nanoparticles in a size range that can interact with cells by being 
adsorbed, binding to the surface, or carrying signal molecules to target 
regions [105-108]. Vast amounts of resources have been allocated to the 
further development of nanoparticle systems with biological applications 
due to the immense number of medical and research opportunities for 
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targeted delivery, activation or tracking systems [109, 110]. MR imaging 
offers a large amount of detail regarding the internal tissues of the body 
however is somewhat limited in its ability to differentiate tissues under 
some circumstances without the aid of an external contrast agent. These 
contrast agents modify the way in which the MR signal is produced from 
the tissues in which it is present and due to the magnetic requirements, 
are often made from or include metals in their composition.  
The magnetic properties of the materials remain the most critical 
aspect of an MR contrast agent; however a nanoparticle behaves quite 
differently to the way in which a chelated Gd contrast agent exploits its 
electron pairs to generate a magnetic dipole. This is due to its generally 
greater size than a conventional contrast agent; however this opens up a 
small window to exploit the way in which the magnetic properties of 
materials change on the nanoscale. 
 
1.3.2 Magnetism on the nanoscale 
A material’s magnetic properties stem from the spin of electrons 
within the atoms that make up the material. The spin of the electron, both 
around the nucleus (angular component) and the rotational spin 
(quantum component) coupled with the –ve charge results in a magnetic 
dipole moment which forms a small magnetic field. In materials that have 
conducive crystal structures, these dipoles can line up and form much 
larger dipoles whose field is equal to the sum of its parts [111].  
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Magnetic domains are present in many metals, only they exhibit 
little or no net magnetic field due to the equal counter alignment of their 
many domain polarities. This can be altered by firmly striking a metal rod 
causing an imbalance in electrons and inducing a temporary dipole, or 
passing the metal through a static magnetic field to force alignment of the 
domains (rubbing a nail on a magnet). Similarly, striking or heating a 
permanent magnet contributes energy to the crystal and allows for 
domains to form and counter align reducing the net magnetic field of the 
material [112].  
The domain wall is the physical solution to reducing the 
magnetostatic energy of aligned dipoles [113]; although forming the wall 
requires energy referred to as ―exchange energy‖, the energy reduction it 
grants is greater than the energy consumed in its formation [114]. In some 
materials the domains do not counter align enough to completely reduce 
the net magnetic field. This is because in highly crystalline materials there 
is often an ―easy direction‖ of magnetisation that runs parallel to one of 
the crystal planes, this results in the familiar ferromagnetic properties of 
fridge and bar magnets. Domain walls require both energy and space to 
form; this is one aspect that can be exploited by the nano-engineering of 
magnetic materials.  
Magnetic domains exist as a result of energy minimisation of 
primarily the exchange and anisotropy energies between individual dipoles 
[112-114]. A single domain material has a very high magnetostatic energy 
associated with it, however if the uniform alignment of the dipoles is 
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broken up into localised domains that allow for flux closure between 
poles, the magnetostatic energy of a system can be reduced (Figure 4). 
These domains are bordered with zones of gradually rotating dipole 
alignments (Figure 5) [111]. Figure 5 illustrates the gradual change in 
dipole direction upon formation of a Neel wall between domains. This 
leads to a defined width of the domain wall, which is governed by 
competition between the exchange and anisotropic energies.  
 
 
Figure 4: Reduction of energy via domain wall counter alignment. 
 
The exchange energy causes the wall thickness to increase, as it 
decreases with less angular difference between neighbouring dipoles [114]. 
While the anisotropic energy increases as the dipole is rotated further 
away from the easy axis, this causes reduction of domain wall thickness. 
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The competition between these two forces balance within a material to 
form domain walls of defined thickness based on both the crystallographic 
and magnetostatic energy of the material [114]. This results in a critical 
particle size of approximately 15-30 nm where a highly crystalline Fe3O4 
nanoparticle can simply not have enough diameter to allow a domain wall 
to form [115, 116]. This stops the particle from reducing its magnetostatic 
energy by forming multiple domains and maintains a higher 
electromagnetic unit per gram (emu/g) value than multi domain magnetic 
materials.  
 
 
Figure 5: Neel wall formation between two counter aligned domains. 
 
Instead, at this size range the dipole can ―flip‖ randomly while under 
no external field influence [117]. In this way the net field of adjacent 
Zones of 
opposing  
polarity
Domain wall
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particles sums to zero as their dipoles cancel out, minimising their energy. 
This is termed superparamagnetisim, whereby a material exhibits no 
magnetic behaviour until an external field applied and all the dipoles 
within the particle set align and produce a high net field [117]. 
Superparamagnetic iron oxide nanoparticles or (SPIONS) demonstrate very 
little coercivity and return to approximately 0 emu/g once an external 
field has been removed. This is highly advantageous for biological and 
industrial applications as the particles do not aggregate due to intrinsic 
ferromagnetic behaviour, hindering dispersion or cell uptake. Therefore by 
manipulating the crystal structure and particle size within the nanoscale, 
the magnetic properties of a common material can be tuned for advanced 
applications. 
 
1.4.1 Functioning of MRI 
MRI imaging has become a very powerful and widely used imaging 
technique for visualising internal organs and structures within the body. 
The instrument exploits the quantum nature of certain atoms within 
tissues in our bodies. Specifically hydrogen nuclei, both due to their 
abundance and that their solitary, positive, spinning proton gives them a 
relatively large net magnetisation vector (NMV) [115, 116].  
With regard to quantum mechanics, spin is one of two types of 
angular momentum a particle can exhibit. Orbital angular momentum 
relates the particle to another point of reference and is often generalised 
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similarly to angular momentum in classical mechanics (L=r p), while spin 
has no analogue in the classical sense and can be generalised as an 
individual particle rotating on its own axis. This generalisation was first 
proposed by Wolfgang Pauli but was not properly named and 
conceptualised until 1925 by Ralph Kronig, George Uhlenbeck and 
Samuel Goudsmit [118]. Pauli then revisited the idea in 1927 and set 
about establishing the appropriate mathematical framework regarding 
spin which was then used by Paul Dirac in 1928 to derive his relativistic 
quantum mechanics [119, 120].  
Spin is a fundamental characteristic of elementary and composite 
particles as well as atomic nuclei. The idea that it represents a value of a 
particle rotating on its own axis is correct in so far as the spins do obey 
the laws outlined by the principles of quantized angular momenta, 
however there were other properties of spin that set it apart from this 
description. Firstly, the direction of a spin can be changed but it can 
never increase or decrease its speed. Secondly, the spin of a charged 
particle is associated with a magnetic dipole moment with a G-factor that 
relates the magnetic moment back to the angular momentum and 
quantum number of the particle. It is this magnetic dipole moment that is 
taken advantage of in the processes required to create an image using an 
MRI scanner. Any particle that has a net charge and is in motion will 
produce a magnetic field; this effect can be attributed to any atomic 
nucleus with an odd mass number (Figure 6). As these nuclei are both 
charged and in motion, they exhibit a net magnetic field as stated by the 
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laws of electromagnetism [116]. Therefore these nuclei can be 
manipulated by application of a static external magnetic field (B0) and an 
RF pulse to produce MR images of tissues within the body [115].  
 
 
Figure 6: Depiction of a spinning charged particle which generates its own magnetic field 
perpendicular to the direction of spin. 
 
When B0 is applied, the magnetic moments of the hydrogen nuclei 
align parallel and anti-parallel with the applied field (Figure 7 panel 2) 
[115, 116]. This ―alignment‖ and ―anti-alignment‖ condition is determined 
by several factors. Given that the quantum physical properties of the 
nuclei are considered in terms of electromagnetic radiation (packets of 
energy as opposed to waves) there are only two energy states the nuclei 
can obtain ―Low‖ and ―High‖; the proportions of the nuclei in these states 
depends on the thermal energy levels of the nuclei [116].  
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Nuclei in the Low state will align parallel with the external field, 
while the High energy nuclei will align in the anti-parallel direction until 
their energy is overcome by the strength of the externally applied field. As 
snap freezing patients prior to imaging tends to be looked down upon by 
sticklers in the health industry, clinical scanners emphasise higher field 
strengths to overcome the majority of the thermal energy contribution 
from the patient [116, 121]. However due to thermal equilibrium, there are 
always more nuclei in the low energy state prior to alignment. As the 
excess of aligned nuclei overcome the NMV of the anti-parallel nuclei in 
the high state, a net moment in alignment with the field is produced 
proportional to the difference between the two populations. This becomes 
the NMV of the patient and is used to generate the MR signal.  
With the net moments of the hydrogen nuclei aligned along the 
same axis, an external RF pulse of precise frequency can be applied to the 
nuclei to cause the excitation and relaxation required to produce the 
signal measured by the scanner. If the RF pulse applied to the nuclei is 
equal to the Larmor frequency of the particle; the pulse is in resonance 
with the nuclei and an energy transfer can occur (Figure 7 panel 3) [115]. 
It is this transfer of energy that causes the magnetic moments to shift 
away from the lower energy state of alignment with the external field to 
the excited state. Once the pulse has been switched off, the nuclei quickly 
begin to return to their ground state of alignment with the external field.  
During this process, the energy adsorbed from the RF pulse is re-
emitted and detected (Figure 7 panel 4), while the magnetic moments of 
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the nuclei return to alignment due to de-phasing [116]. This process 
produces what is termed ―T1 recovery‖ as the nuclei give up their energy 
to their immediate environment during spin lattice relaxation. The nuclei 
recovery rate is exponential and referred to as the ―T2 relaxation time‖. T2 
relaxation or ―spin-spin‖ relaxation results from nuclei exchanging energy 
with adjacent nuclei [115]. This process is outlined in the diagram below. 
 
 
Figure 7: The four stages of signal production: (1) nuclei at rest randomly aligned, (2) 
alignment by the external magnetic field B0, (3) excitation by the RF pulse and (4) 
relaxation and signal emission. 
 
With the B0 and tissue temperature being static, the RF pulse power 
and duration becomes the critical factor in the imaging process [116]. The 
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repetition time (TR) controls the gap between pulses and available time for 
the nuclei to relax before the application of the next pulse for individual 
slices of the scan, which is measured in milliseconds (ms); TR determines 
T1 relaxation [116]. The echo time (TE) represents the required time from 
the pulse input to the peak of output signal which determines the amount 
of transverse magnetisation decay that occurs between pulses, hence the 
amount of T2 relaxation which is also measured in ms [116].  
 
1.5.1 Weighted images 
1.5.2 Contrast 
Contrast within an image is defined as having both saturated bright 
and dark areas of no signal. Between these extremes, intermediate shades 
occur and make up the bulk of the image. Within each slice of the image, 
the NMV can be segregated into differing vectors from various tissues in 
the patient, discerning the difference between fat, muscle, cerebrospinal 
fluid and water. High signal is produced by the tissue having a large 
transverse magnetism component which results in a bright signal. 
Conversely, low signal is generated from tissues that have a small 
transverse component; typically the two extremes of this principle are fat 
and water [116]. 
Water is hydrogen directly linked to oxygen which strongly attracts 
electrons away from the hydrogen atom making it more susceptible to the 
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effects of B0, while fat is made up of hydrogen linked to carbon in large 
lipid molecules. In the case of fat, the carbon doesn’t attract the electrons 
away from the hydrogen as strongly, rendering the hydrogen more 
protected from the effects of B0 by its electron cloud [116]. Subsequently 
hydrogen in fat recovers more quickly than hydrogen in water and both 
differ in brightness in MR images. There are three mechanisms used to 
produce contrast within MR imaging, T1 recovery, T2 decay and 
proton/spin density (total number of protons per unit volume). 
MR images can be ―weighted‖ differently; this means that the 
parameters can be changed so that different tissues appear bright or dark. 
A T1 weighted image relies on the difference between the T1 times of fat 
and water [116]. T1 imaging employs a shorter TR between pulses and 
yields more signal from fat, creating bright spots for fatty tissues. In T2 
weighted imaging, the TE is the defining signal that determines contrast; 
the TE is longer in water than it is in fat and as such produces more 
signal and bright areas high in water content. Hence either a T1 (fat bias) 
or T2 (water bias) image can be produced by changing the imaging 
parameters [116] (Figure 8). 
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Figure 8: Comparison of T1 (A) and T2 (B) weighted imaging of the same 
axial slice of the brain demonstrating the contrast comparison between 
tissues using either weighting regime. 
 
T1 and T2 imaging modes can be useful when detecting certain 
pathologies within a tissue. Tumour sites tend to have higher water 
concentration than surrounding tissues and as such appear bright under 
T2 weighted imaging, allowing the site to be identified from other 
structures in the tissue. There are however many pathologies that are 
difficult to identify without the aid of an external contrast enhancement 
agent, that affects either the T1 or T2 characteristics of the tissue. 
Contrast agents function based on dipole-dipole interactions and 
magnetic susceptibility [116]. In general, contrast agents have large 
magnetic moments that affect the local magnetic fields of protons [115]. 
Magnetic susceptibility is a fundamental property of matter and reflects 
the extent to which the nucleus can be magnetised by the application of 
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an external magnetic field. ―Enhancement‖ of a T1 weighted image is 
achieved by reducing the T1 relaxation time of nearby protons, 
brightening the nuclei in the presence of the agent. While as T2 contrast is 
based on shortening the T2 decay time, this can be achieved by a material 
that has a highly positive magnetic susceptibility [115].  
Contrast in this case, is increased by reducing the signal from 
protons under influence of B0, darkening the area [115]. An example of 
these agents is the paramagnetic gadolinium based agents for T1 and 
ferromagnetic substances such as Ferridex™ for T2 weighted contrast. 
These materials are used to further enhance the contrast produced during 
imaging of tissues or pathologies that would otherwise be difficult to 
distinguish, such as tumours, infection, infarction, inflammation or post 
traumatic lesions (Figure 9) [115, 116]. The magnetic properties of 
common contrast agents can fall under several different classifications, 
paramagnetic, superparamagnetic and ferromagnetic.  
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Figure 9: MR image taken with and without contrast agent. The right hand image shows 
a haemorrhage as injected contrast agent has leaked from a broken blood vessel this aids 
diagnosis of conditions that would otherwise be unnoticed in the non-contrast enhanced 
image. Image courtesy of http://www.modernfaqs.com [4] 
 
1.6.1 Types of magnetism 
Paramagnetic materials result from unpaired electrons within an 
atom, these unpaired electrons produce a very small magnetic moment 
around the atom; however these moments orient randomly and cancel 
each other out. While in the presence of B0, the moments align and 
produce a bulk NMV and express a positive magnetic susceptibility, 
enhancing the strength of the local field. Gadolinium (Gd) is an ideal 
paramagnetic contrast agent as it has seven unpaired electrons that cause 
a decrease in T1 and T2 relaxation times in surrounding atoms [123]. 
Unfortunately Gd in its elemental form is highly toxic and requires 
chelating compounds to reduce its potentially toxic effects. Although Gd 
chelates are commercially available and commonly used, there have been 
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concerns regarding chelate disassociation post injection causing toxicity. 
Links between Gd contrast agents and the deaths of patients due to 
nephrogenic systemic fibrosis has been reported in patients who received 
Gd chelates while suffering kidney damage [124].  
Superparamagnetism is similar to that of ferromagnetism / 
ferrimagnetism but only occurs in sufficiently small nanoparticles. If a 
ferromagnetic material such as iron is confined to a small enough size, its 
magnetisation direction can flip randomly due to the influence of 
temperature. While these random flips are occurring, no net field is being 
produced. If an external field B0 is applied, these magnetic moments can 
align and produce a much stronger magnetic susceptibility than 
paramagnetic materials. Several types of superparamagnetic agents are 
being researched or are available for clinical use, such as magnetite, 
Fe3O4; maghemite, γ-Fe2O3 ; and haematite α-Fe2O3; as Feridex, Sinerem 
and Magnevist respectively, however none of these are available in 
Australia currently. 
 Fe is a common element found in our bodies and is able to be 
broken down through an excess iron biological excretion pathway [125]. 
However, due to technological limitations the size of these iron oxide 
particles has limited their usage to gastrointestinal lumen, liver and 
spleen imaging. This is due to the particles being too large to remain in 
blood circulation long enough as they are rapidly removed by first pass 
metabolic processes [126, 127]. Recently these technical limitations are 
being overcome and new iron based magnetic particles are being produced 
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using method capable of controlling size and surface chemistry [128-131]. 
Tailoring the surface chemistry is an important step in increasing both 
biocompatibility and allowing possible molecular targeting for cell specific 
applications. This can be greatly beneficial as MRI already has 
exceptionally high spatial resolution, but the ability to target certain 
pathologies with contrast agent, makes this diagnostic tool far more 
attractive [102].  
 
1.7.1 Production methods of magnetite 
1.7.2 Aqueous co-precipitation 
The co-precipitation method for forming Fe based nanoparticles is 
the simplest and generally most effective chemical route. Originally 
developed by Massart in 1981 [132], his process yielded very poor 
monodispersity but was performed without the use of stabilisation 
molecules. Now refined and using stabilising molecules, this method can 
be used to fabricate either Fe3O4 or γFe2O3 particles by aging 
stoichiometric ratios of ferrous and ferric salts in an aqueous medium at 
relatively low temperatures (60-120°C). 
Fe2+ + 2Fe3+ +8OH- → Fe3O4 + 4H2O (1) 
Equation 1 demonstrates the basic principle by which this process 
yields product, given the thermodynamics of this reaction, precipitation 
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should occur within the pH range of 8-14 with a molar ratio of Fe3+/Fe2+ 
being 2:1 in a non-oxidising environment [133]. The Fe3O4 produced from 
this reaction remains unstable and can be readily oxidised into 
maghemite in the presence of oxygen as shown in equation 2. 
Fe3O4 + 2H+ → γFe2O3 + Fe2+ + H2O (2) 
As such, the process must be carried out in an oxygen free 
environment to avoid hematite or maghemite formation [134]. Maghemite 
forms as a result of oxidation and has been found to have reduced 
magnetic properties. Therefore oxidation should be avoided while 
pursuing magnetic product with a high emu/g value [134]. Magnetic 
properties of metals depend largely on crystal structure and as magnetite 
and maghemite differ on their spinel structure their magnetic properties 
vary. Magnetite fully occupies the octa and tetrahedral sites, while 
maghemite possesses cationic vacancies in the octahedral site lowering 
symmetry within the structure [135].  
This difference in symmetry gives rise to the different magnetic 
properties of the two materials. The two oxide states are difficult to 
identify using techniques such as XRD given their exceptionally similar 
patterns therefore sample purity is difficult to determine [136]. As 
maghemite is expected to form to some extent during any process to 
produce magnetite, reported values for magnetisation saturation between 
the two materials tends to vary but generally measurements of bulk 
materials yield values of ≈ 90 emu/g-1 for magnetite and ≈ 65 emu/g-1 for 
maghemite [136]. 
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Fe3O4 particles are crystalline structures and in general, grow in 
accordance to the rules and behaviours of crystal formation systems. 
These rules suggest that for homogenous particles to be produced, two 
distinct phases of particle formation must be separated, nucleation and 
growth. Usually the nucleation phase begins as particle seeds precipitate 
out of a supersaturated solution, the solution concentration drops as a 
result and the precipitation ceases, leaving a set amount of nanoparticle 
seeds. The growth phase occurs as solutes diffuse from the solution to the 
surface of the seeds, keeping these two phases separate and controlled 
generally leads to higher monodispersity within the particles produced 
[137].  
The co-precipitation method can yield large quantities of 
nanoparticles fairly efficiently (approx. 50% yield). This is advantageous 
for imaging applications as large quantities are required for human 
administration; however as kinetic factors are the only controls, the 
particle size distribution is difficult to tailor and reproduce. For this 
reason, when highly monodisperse particles are required this method is 
superseded by others. Due to the production process, nanoparticles 
fabricated via the co-precipitation method incorporate polymers, lipids or 
dendrimers onto their surfaces which impart particle stability and 
reduced aggregation. These surface coatings also present various 
attachment sites for later modification for targeting applications.  
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1.7.3 Reactions in constrained environments 
Constrained environment reactions are similar in principle to co-
precipitation processes, except that these processes involve using either 
synthetic or biological nanoreactors to add additional control to the 
process via direct physical confinement. These methods were developed in 
an attempt to improve the monodispersity of the particle product. This 
process has been demonstrated using amphoteric surfactants in non-
polar solvents to create water swollen reverse micelles [138-144] and 
phospholipid vesicles using FexOy particles as supports [145, 146]. An 
added advantage of this process is that the molecules used to restrict and 
control the growth of the particles, may also act later on as a surface 
coating; providing stability or desirable surface characteristics. 
Controlling the morphology of the fabricated particles using this 
method can be achieved primarily by modifying the reactor shell. 
Amphiphillic molecules such as lipids have opposing polar charges on the 
molecule (hydrophilic/polar head – hydrophobic/non-polar tail). This 
causes spontaneous formation of micelle or liposome structures 
depending on the solvent [147]. The final spherical structures arise as a 
stacking issue between the broad head and narrow tail, resulting in a 
spherical formation. Given that the curvature of the structure is 
proportional to the head width vs. tail length ratio, modifying these 
characteristics of the lipids gives control of overall reactor size.  
These reaction encapsulation principles have also been investigated 
using dendrimers and cyclodextrins [148, 149]. Similar to amphiphilic 
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molecules, dendrimers have head and tail groups, but also possess a 
branching side chain. In most examples, dendrimers are added during the 
magnetic particle synthesis to form a surface coating that infers stability 
in water. Magnetic materials produced in this way are referred to as 
―magnetodendrimers‖ and have found applications in several medical 
fields such as MR imaging and cell tracking [129]. The polymer coating in 
this case has a high affinity for cellular membranes due to its surface 
charge, resulting in a high rate of non-specific particle uptake [150-152]. 
Lipid molecules can be used to form a bi-layer based liposome to 
encapsulate the nanoparticle after formation. Lipids usually have a polar 
head group and two fatty acid chains forming the hydrophobic tail, iron 
oxide particles encapsulated in this manner are referred to as 
magnetoliposomes [152]. Lipid bilayers are highly functional given their 
ability to simply add specific molecules to the outer membrane for either 
cellular targeting, reducing RES clearance or drug loading directly onto 
the lipid surface [135]. 
Various other materials such as PEG have been used to reduce the 
overall diameter of the magnetic particles and to prevent further oxidation 
[153]. PEG is known to maintain particle stability by reducing 
intermicellar interactions by minimising the interfacial free energy of the 
core, preventing aggregation [154]. The increased circulation time of 
particles using polymeric molecules is attributed to the large hydrophillic 
corona formed around the core which prevents opsonin adsorption, 
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reducing the visibility of the particles to phagocytes, decreasing clearance 
by the liver and spleen [155].  
The primary advantage of reverse micelle or nanoreactor fabrication 
techniques is that a wide variety of shapes and surface features can be 
formed by variations in surfactant/co-surfactant or reaction conditions 
[156]. While these materials have demonstrated excellent capabilities, they 
remain relegated to pre-clinical testing. It is most likely due to the inability 
to produce the large amounts of material required for human 
administration due to difficult synthesis methods. 
1.7.4 Sol-gel 
Given the success of constrained environment fabrication 
techniques, it is no surprise that the sol-gel process has also been applied 
to iron oxide nanoparticle formation. Similarly, the sol-gel method uses 
two distinct phases (in this case liquid-solid) to control the reaction 
kinetics of the growing particles [157, 158]. Due to the nature of the 
reaction process, the nanometric particles (sol) are formed within a 
restrictive matrix of the supportive ―gel‖, as the reactions are commonly 
performed at room temperature; later heat treatments are required to 
refine the crystalline state of the material.  
The kinetics of the sol gel process are primarily governed by solvent 
temperature, pH and concentration of salt precursors [159-161]. γFe2O3 
particles with a size range between 6-15 nm have been fabricated via this 
route [162]. This process does offer some advantages, such as the 
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products structure being highly controllable and determined by reaction 
conditions. Sol- gel techniques also yield monodisperse materials with 
good control over particle diameter, with the flexibility to embed the 
product into an inert matrix such as silica during the fabrication process 
[163, 164]. However the multi stage fabrication steps, environmental 
dependencies, including the high temperature heat treatment (up to 
400°C), make it a cumbersome method to quickly establish a reproducible 
protocol for good yield. 
 
1.7.5 Thermal decomposition 
Given the requirement for product monodispersity, high 
temperature thermal decomposition methods have been investigated [135, 
165-167]. The principle employed is the decomposition of an 
organometallic compound in a high boiling point solvent in the presence of 
a stabilising agent. The high temperatures required to begin to decompose 
the metal salts allow for precise control of the nucleation and growth 
phases of particle formation [135]. While the final morphology of the 
particles can be modified by altering ratios of the starting reagents and 
duration of high temperature aging process [168]. This process was 
inspired by the use of thermal decomposition to produce high quality 
semiconductor crystals in in organic media [169, 170].  
A wide range of metal precursors are able to be utilised such as 
acetylacetonates, metal cupferronates, carbonyls [171] as well as simple 
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non-toxic metal chlorides [172]. This method can also be utilised to 
produce metallic nanoparticles which are of interest in areas such as data 
storage due to their higher net magnetisation compared to their oxide 
counterparts [173]. Butter et al. produced polymer stabilised metallic Fe 
particles ranging from 2-10 nm by the thermal decomposition of [Fe(CO)5] 
in the presence of polyisobutene under a nitrogen atmosphere [173]. The 
particles remained exceptionally stable in water, however were still 
susceptible to oxidation given the change in susceptibility measurements 
along with the increase in particle size [168].  
Notably, in 2004 Park et al. published a concise method to produce 
gram quantities of spherical magnetite nanoparticles with an exceptionally 
narrow size distribution using thermal decomposition of a metal-oleate 
[165]. This process used a two-step synthesis in which the metal oleate 
was first produced using a non-toxic precursor such as iron chloride and 
sodium oleate instead of using precursors such as pentacarbonyls which 
have been found to be potentially toxic [174].  
The process involved thermal decomposition of the iron-oleate 
complex in the presence of oleic acid in 1-octadecene as a solvent at 
320°C. The monodispersity of the product produced was attributed to the 
considerable enthalpy gap between the nucleation and growth phases. 
These processes occurred separately as a result of the disassociation of 
one of the three oleate ligands at 200-240°C by CO2 elimination which 
triggered the nucleation phase. The remaining two oleate ligands remained 
attached until 300°C, after which the main growth phase initiates. This 
53 
 
process produced 5–22 nm spherical particles after 30 min of aging at 
320°C, increasing the aging duration caused a shift in morphology to 
hexagonal/cubic particles [165]. Unfortunately the particles produced in 
this manner remain capped with oleic acid and as such remain 
hydrophobic. In order to use these materials in biological systems, post 
fabrication techniques are required to infer the appropriate surface 
characteristics for solubility in water.  
The thermal decomposition method is also able to produce particles 
of differing morphology. Dumestre et al. utilised thermal decomposition to 
produce cubic nanostructures with controllable size and shape. Their 
group achieved this by decomposing Fe(N(Si(CH3)3)2)2 and H2 when 
combined with oleic acid or hexadecylammonium chloride in the presence 
of hexadecylamine at 150°C [175]. They established that variations in the 
ratio between the acid ligand and amine slightly altered the edge length of 
the particles from 7 - 8.3 nm. The group also found that the cubic 
structures formed crystalline superlattices with aligned axis whose 
interparticle spacing varied (1.6 – 2 nm) in relation to the edge length of 
the individual particles forming the lattice [175]. Similar particle tuning 
abilities were also reported by Puntes et al. in the fabrication of cobalt 
nanodisks by thermal decomposition of cobalt carbonyl in the presence of 
linear amines [176]. Nickel and cobalt nanorods can also be formed using 
this technique as demonstrated by Dumestre et al. They demonstrated 
that not only could they produce cobalt nanorod structures by 
decomposition of [Co(η 3-C8H13)( η4-C8H12)] but that these particles would 
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self-assemble into superlattices when formed in the presence of 
trioctylphosphane oxide [177, 178]. All the fabrications methods are 
summarised below in table 1. 
 
Synthetic 
method 
Synthesis Reaction 
period 
Solvent Size 
distribution 
Shape 
control 
Yield 
Co-
precipitation 
Easy, 
ambient 
conditions 
Minutes Water Moderately 
narrow 
Poor High 
scalable 
Microemulsion 
Sol-gel 
Complicated, 
ambient 
conditions 
Hours Organic 
compound 
Moderately 
narrow 
good Low 
Hydrothermal Simple, high 
pressure 
Hours 
Days 
Water 
Ethanol 
Very narrow Very 
good 
Moderate 
Thermal 
decomposition 
Complicated, 
inert 
atmosphere 
Hours 
Days 
Organic 
compound 
Very narrow Very 
good 
High 
scalable 
Table 1: Comparison of advantages/disadvantages of the differing magnetite nanoparticle 
fabrication techniques. 
 
Given the requirements for MRI contrast agents to have high net 
magnetisation, narrow size distribution, small size, high product yield and 
biocompatibility, we felt that the method outlined by Park et al best suited 
our needs [165]. A post fabrication step would be required to infer the 
appropriate solubility in water however the requirement of this additional 
step was outweighed by the overall physical properties and high yield this 
method offered. 
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1.8.1 Desired characteristics for MR 
applications 
 
1.8.2 Magnetic properties 
The MR imaging process exploits the magnetic interaction of nuclei 
with an external magnetic field; contrast enhancement is achieved by a 
material that alters this interaction and is fundamentally based on the 
magnetic properties of that material [116]. Materials that exhibit 
superparamagnetisim offer some of the best magnetic properties for this 
application, given their effective ―switching‖ between magnetic and non-
magnetic states with the application of an external field [116, 179].  
They have also shown the ability to possess the high saturation 
magnetisation values required to generate a larger net effect on 
surrounding protons during the imaging process. The saturation 
magnetisation is measured in (emu/g), materials with higher emu/g 
values cause a reduction in T1 and T2 relaxation rates [131]. Therefore, a 
material with higher emu/g value will increase the contrast locally on a T2 
weighted image. A wide range of emu/g readings have been reported for 
magnetite nano particles, most range from 30-50 emu/g which is lower 
than the 90 emu/g recorded for bulk magnetite [168, 180].  
Three main factors are involved in contributing to the magnetisation 
saturation of magnetite nanoparticles, these are particle size, crystal 
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structure and particle spacing [181]. The particle size and crystal 
structure varies between fabrication conditions and process used, how 
these factors affect the magnetisation saturation of the particles has been 
discussed previously. However particle spacing is dependant almost solely 
on post fabrication coatings that act to reduce the interaction between the 
individual magnetic domains. By separating the particles, each unit is 
able to behave as an individual domain that aligns with the applied field 
rather than an aggregate of domains with a net field [180]. 
Magnetite particles produced by thermal decomposition possess 
these attractive properties, however, without a secondary surface material, 
are unable to be applied to biological applications due to their non-
favourable behaviour within the biological environment. For magnetite 
particles to be applicable to biological applications they must also possess 
desirable biological properties such as low toxicity and high particle 
stability in biological media [179]. To achieve this, a surface coating is 
required to infer these properties to the particles; surface coatings also 
offer attachment sites for targeting or labelling molecules [182]. Magnetite 
surface coatings are commonly organic compounds that isolate the core 
from the external environment [123, 135, 183]. 
 
1.8.3 Bio-distribution 
Bio-distribution of a material or compound is exceptionally 
important for any nanomaterial with medical applications. There are 
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different bio-distribution requirements for various applications, such as 
specific site localisation in the case of targeted MR contrast or systemic 
distribution for certain pharmacological compounds. Each requirement 
has its own challenges presented by the mammalian body.  
Intravenously administered MR contrast media must be able to both 
localise at a desired site, to provide the relative contrast, while avoiding 
uptake and excretion by the RES. This uptake results from the quick 
response of phagocytes that rightly identify the injected particles as 
foreign bodies and begin consuming the particles via phagocytosis [184, 
185]. However, given that the highest amount of phagocytes are found in 
the liver (approx. 90%), this behaviour while detrimental to distributing 
the particles to other parts of the body can be used to condense large 
amounts of contrast agent within the liver to aid in MR imaging of the 
problematic organ [186].  
Other areas of the body also naturally take up large numbers of 
particles due to phagocyte activity and can subsequently enhance their 
relative contrast under MR imaging such as the spleen, lymph nodes and 
bone marrow [187]. This process of phagocytic removal is proportional to 
both the surface properties and size of the particles with larger and more 
highly charged particles being removed faster [126].  
Particle size has been found to have a considerable effect on bio-
distribution. In general it has been established that 90% of particles with 
a diameter greater than 60 nm are removed from the blood by 
phagocytosis occurring in the liver after 30 minutes [125, 188]. Whereas 
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organs such as the lungs, brain and kidneys show minimal or non-
detectable amounts of iron oxide nanoparticles [188]. This distribution 
behaviour can be altered by reducing the particle size and altering the 
surface coating of the materials [126, 188]. If the application requires that 
the injected particles localise at another part of the body other than the 
liver, spleen or bone marrow; size and surface modifications are required 
that enable the particles to evade the RES long enough to complete their 
function. An increase in the blood half-life of iron oxide particles in 
relation to both size and surface coating has been reported by several 
groups [189, 190]. Overcoming the initial RES response allows particles to 
begin to localise at different parts of the body and opens the door for 
target specific localisation of particles throughout the body. It was found 
that increasing the blood half-life of particles caused distribution to move 
to areas such as the kidneys, spleen, lungs, heart instead of %90 uptake 
within the liver [131, 191].  
One key aspect of iron oxide nanoparticles is their biocompatibility, 
as iron is an essential element required by the body it can be adsorbed 
and broken down by normal metabolic cycles. The particles coalesce in 
the liver for approximately 3 days and 4 days in the spleen [125, 131, 
191]. The particles are stored in the lysosomes of the phagocytes that 
consumed them until they are broken down and are assimilated by the 
normal iron metabolism and incorporated into the haemoglobin of 
erythrocytes [131].  
 
59 
 
1.9.1 Surface modification of magnetite 
Given the nature of the MR process and the properties of magnetic 
nanomaterials, an abundance of applications has begun to be investigated 
within the field. Contrast enhancement, targeted imaging, dual imaging 
and therapeutic delivery have all been investigated using various 
nanoparticle systems [89, 91, 95, 127, 186, 192, 193]. Bio-medical 
applications require attentive detail regarding their biological interface, for 
both colloidal stability within biological systems and toxicity.  
Surface properties of nanomaterials can greatly vary their possible 
application; as well as imparting excellent colloidal stability. Without a 
suitable surface coating, some iron oxides are hydrophobic, therefore in 
water based solutions, large clusters and agglomerates form due to the 
hydrophobic interactions between particles [194]. This process produces 
clusters with a strong magnetic dipole – dipole attraction which begin to 
exhibit ferromagnetic properties as the cluster size increases [194]. With 
an increase in cluster size, the single domains of the individual particles 
are lost and the net magnetisation of the material is reduced [195]. Given 
these factors, surface coating of the magnetic particles is imperative in 
order to maintain their efficacy for biological applications. Given the wide 
range of potential applications for magnetic nanoparticles, many surface 
coatings have been investigated for uncoated particles to enhance their 
desirable properties. As several surface coatings such as dendrimers and 
lipids have already been discussed, only a brief description of three 
common surface coating techniques will be covered in this section. 
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1.9.2 Dextran 
Dextran is a polysaccharide composed of α-D-glucopyranosyl units 
that can be modified in both its length (1000 – 2,000,000 Da) and may 
contain branches formed from its α-1,3 linkages. Dextran has been 
commonly used to reduce blood clotting in surgery, as a parenteral 
nutrition source, lubricant in eye drops and to apply osmotic pressure to 
biological molecules. It has been found to be exceptionally biocompatible 
while having a long blood circulation time [182]. The dextran layer is 
degraded in the body by intracellular dextranases within macrophages; in 
general this occurs to the greatest degree within Kupffer cells and is 
excreted in the urine [196]. As the iron oxide is incorporated into the 
body’s iron store [197], the combination of the iron oxide core and 
biocompatible surface coating is very advantageous. Dextran sulphate has 
been applied as a surface coating to promote particle uptake by 
macrophages, given its interaction with the membrane receptor (SR-A) 
[198]. This property can be exploited to aid in imaging atherosclerotic 
plaques as the nanoparticle laden macrophages are known to be first 
responders to plaque deposits [199, 200]. For these reasons, dextran 
coated magnetic particles have been able to pass industry regulation 
standards and have translated into products available on the market. 
Some examples of these are carboxydextran coated magnetite, 
Ferucarbotran (Resovist® Japan and Europe) and dextran coated 
magnetite and ferumoxides (Endorem® – Europe, Feridex® in the USA 
and Japan). 
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1.9.3 Carboxylates 
Carboxylates have been utilised to stabilise the surface of 
nanoparticles due to their solubility in aqueous media. The coating 
process described by Sahoo et al. results in one or two of the carboxylate 
groups co-ordinating to the magnetite surface dependant of environmental 
pH of the reaction. This leaves at least one of the three carboxylate groups 
free to interact with the solvent; this group carries the surface charge that 
infers the desired hydrophilicity and stability [201]. The availability of the 
carboxylate surface charge provides anchorage sites for additional 
molecules for labelling or targeting such as antibodies or fluorescent dyes. 
Another commonly used carboxylate coating is dimercaptosuccinic 
acid (DMSA). Similarly to citric acid the conjugation occurs through 
available carboxylic groups, however the overall stabilisation of the 
particle is a result of intermolecular disulphide crosslinking between 
surface ligands [181, 202]. DMSA coating provides biocompatibility, 
stabilisation and both carboxylic acid and thiol groups available on the 
surface for further functionalization with desired molecules or 
components [202]. DMSA surface coatings will be discussed further in 
chapter 5 section 5.2.1 
 
1.9.4 Silica 
Silica or (silicon dioxide) is an oxidised metalloid of silicon, found 
abundantly in nature, in its native form it is almost chemically inert. 
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Stöber was the first to produce silica spheres in the micron range [203], 
these materials were subsequently used in abrasives and ceramic 
additives. Further refinements to the process yielded greater control of 
particle diameter and surface morphology. This opened up applications in 
biology using the particles as drug carriers and template materials for 
fabrication of nano capsules [86]. However silica can also be used to coat 
the surface of iron oxide nanoparticles contributing several beneficial 
properties [204]. The physical barrier produced by the silica coating 
provides protection from the short range dipole interactions produced by 
the magnetic moments of surrounding magnetic particles [204].  
This is due to the magnetic dipole interaction being proportional to 
1/(distance between dipoles)3 [205]. Without the silica coating the 
particles would aggregate due to interactions with biological media and 
this would lower their exchange energy whilst under an external field. The 
silica coating also infers a negative surface charge which allows particle 
dispersions up to high particle densities ranges [206]. These properties 
have been attributed to strong, short range Stern layer forces, produced 
by (OH¯) groups on the silica surface which render the surface of each 
particle negatively charged [206].  
The negative charges present on the surface reduce particle 
interaction due to electrostatic repulsion. These forces have been found to 
influence a range of up to 4 nm into the solvent and are strong enough to 
reduce the dispersion interaction between particles [207, 208]. These 
silanol groups can be functionalised to allow biomarkers to be tethered to 
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the surface, either by using covalently bonded coupling agents or 
electrostatic forces to adhere molecules [209].  
Silicon dioxide has also been demonstrated to be biocompatible 
[210, 211] and as a result, a silica coated iron oxide product has been 
developed and brought to market for gastro intestinal imaging under the 
name Gastromark® [210, 212]. This biocompatibility has also widened its 
biological applications to gene transfection agents [213, 214], drug 
delivery systems [215, 216]. SiO2 is also highly chemically stable even in 
the presence of strong acids such as nitric and sulphuric acid. 
Hydrofluoric acid (HF) is one of the few acids capable of dissolving SiO2 
and for this reason it has been used as a protective/sacrificial layer in the 
lithographic process of the semiconductor industry. The abilities of 
selective removal, chemical and physical stability also make SiO2 an 
excellent template material for nanoparticle synthesis. 
The main routes of silica surface coating stem from the original 
Stöber process [203], in which a silica precursor such as teteraethyl 
orthosilicate (TEOS) in water and ethanol undergo a base mediated 
hydrolysis to form micrometre sized spherical silica particles. A more 
detailed description of this process is given in section 1.8.5.  
This process was later extended to particle coating by using the 
desired core particles as a template for the hydrolysis product of silica. 
Using this technique, silica shell thickness can be tuned so as to maintain 
size uniformity within the product. Coating thicknesses varying between 
2-100 nm have been reported [183, 217] without additional stabilising 
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molecules or surfactants. Therefore product can be easily centrifuged from 
the growth solution without the need for complicated washing steps.  
Another common methodology for silica coating iron oxide particles 
is using the particles as seeds for a microemulsion based process similar 
to the method established by Massart [132]; initially used to grow the iron 
oxide particles in constrained environments [144, 218-220]. However this 
process is only capable of yielding polydisperse particles and the 
surfactants used require extensive washing steps to ensure 
biocompatibility [221, 222]. This makes them more difficult to translate to 
the clinical setting due to volume requirements of the application. 
 
1.10.1 Stöber method of silica growth 
Given that this thesis will investigate the application of the Stöber 
method in the coating of iron oxide nanoparticles, a more detailed 
description of the process and its subsequent application to particle 
coating will be discussed here. 
The Stöber method first described by Werner Stöber in 1968 was 
used to produce monodisperse spherical SiO2 particles and has since been 
improved to reproducibly fabricate particles ranging from 50 – 2000 nm in 
diameter [203]. The process consists of hydrolysing the silyl ether present 
on a silicate ester, commonly tetraethyl orthosilicate (TEOS), in a mixture 
of alcohol, water and ammonia to produce particles. There are two 
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conflicting models used to describe the growth process of the SiO2 
particles, each with seemingly proven experimental grounding. The La Mer 
model describes the process as monomer addition, in which nucleation 
occurs rapidly during the initial stages, after which the particle diameter 
increases as growth becomes the dominant reaction [223-225]. This offers 
one model to describe the homogeneity of the particles produced by the 
process. An alternate theory is called controlled aggregation and differs in 
that it describes the growth of the silica particles as the result of 
aggregation of primary particles, and that final diameter is not only 
determined by reaction rates, but also by the size and colloidal stability of 
the primary particles [226-228].  
SiO2 grown in this manner has demonstrated the ability to have its 
deposition controlled both in rate and structure, giving rise to the ability 
to create defined nanostructures with solid or porous morphologies [86]. 
The surface of the silica surface also presents an external negative charge 
in the form of silanol (Si—OH–) which offer electrostatic attraction and 
attachment sites to positively charged molecules. Specific adsorption 
allows for certain molecules to be adsorbed onto the surface or into the 
pores of a silica structure which can later be released or combined with 
additional molecules in a ―layer by layer‖ approach [229]. If the silica 
offers no more functionality it can simply be selectively removed by 
etching in HF or potassium hydroxide to leave behind the polymers 
templated by the silica creating, structures with application in drug 
delivery, micro-reactors and lab on chip devices, [230-232]. 
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1.11.1 Cellular targeted nanoparticles 
Cell specific nanoparticle internalisation is a research area just 
coming out of its infancy with a range of groups publishing 
demonstrations of the principle [233-238]. The process hinges on isolating 
a surface marker present on the target cells but one not expressed on the 
surface of others, or at least expressed to a far lower extent. Conveniently, 
some cancerous tissues have a tendency to over express certain surface 
proteins, making them viable targets for antigen modified nanoprobes.  
Breast tumours are typically classified by histo-pathological grade, 
type and stage; these factors are used to determine the prognosis and 
viable treatment pathways such as chemo, adjuvant or immunotherapy. 
The tumour types are classified based on the epidermal growth factor 
receptor (EGFR) family of tyrosine kinase receptors which contains four 
distinct groups, human epidermal growth factor 1 (EGFR/HER1), HER2, 
HER3, and HER4 [239].  
These receptors are expressed in many different tumour types to 
different levels. HER2 has been extensively studied given its prevalence on 
the surface of particularly aggressive tumours that have poor prognosis 
[239]. In the case of many of these aggressive cell types, HER2 is 
overexpressed several orders of magnitude greater than in non-tumorous 
cells. This overexpression can be used as a marker to identify these cells 
from their surroundings, an attribute that has been exploited for 
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treatments such as Herceptin® [240-242]. Herceptin® is a tumour specific 
immunotherapy used in adjuvant and neoadjuvant treatments; it has 
demonstrated the ability to stimulate the immune system to attack HER2 
expressing tumours; however some patients begin to develop resistance to 
the treatments.  
Herceptin® was approved by the FDA in 1998 for the treatment of 
HER2 positive breast cancers. Herceptin® is a monoclonal antibody 
developed to target the extracellular domain of the HER2 surface protein 
which was later humanised for clinical use [243]. Although the HER2 
receptor is expressed by normal cells, it is expressed up to 100 times more 
in many cancerous cells [244]. This large expression variation is the basis 
of the success of the Herceptin® treatment, however little is known about 
the exact method of action the Herceptin® uses to cause cell death in the 
cancerous cell. The consensus of the literature indicates that Herceptin® 
functions by binding and being subsequently internalised via receptor 
mediated endocytosis. After this phase it is thought to cause cell cycle 
arrest by down regulating HER2 which leads to a decline in cell 
proliferation, suppression of angiogenesis and cell death. However this 
mode of action is also an Achilles heel of the treatment, treating the 
cancer in this specific way does put additional pressure on the cancerous 
cell population to reduce the number of HER2 surface proteins, which is 
the action specifically driven by the treatment. This results in an increase 
in cancerous cells that express lower levels of HER2 and thus avoid 
treatment. For this reason the treatment is usually used in combination 
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with chemotherapy where a synergistic effect has been observed when 
used in conjunction [245]. 
Although Herceptin® performs as a cancer treatment in its own 
right, its ability to specifically target the surface of certain cancerous cell 
lines can be utilised as a targeting moiety for a nanoprobe. The targeting 
ability of the Herceptin® can be harnessed by conjugating it to the surface 
of a nanoprobe which is subsequently internalised by the cancerous cells. 
These guided nanoprobes can serve several functions ranging from drug 
carriers, contrast enhancement and functional particles such as induction 
heating active materials [246-252]. However few of the applications have 
developed far enough to be applied in the clinical environment. The most 
basic of these applications involves coating a magnetic or radioisotope 
labelled nanoparticle in conjunction with Herceptin® to enhance the local 
contrast of MR or PET at cell specific locations.  
Currently several iron oxide based materials have been applied to 
targeted MR contrast, however the materials used lack the physical 
attributes required to be clinically useful. This is mostly due to the 
particle size being too large, thus causing rapid clearance from the blood 
by the RES. The current materials also suffer from poor homogeneity and 
low magnetisation, hence large dosages are required in order to achieve 
contrast [253-255].  
Several studies have successfully demonstrated the adhesion of 
Herceptin® to iron oxide based nanoparticles for targeted imaging. 
However in each case limitations of the materials have held the product 
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back from advancing towards clinical studies such as small production 
scale, low magnetisation or reduced contrast enhancement [256]. One 
study by Chen et al. [256] showed that the magnetite particles possessed 
a low magnetisation saturation value and even though they successfully 
targeted HER2 expressing cells, the particles were only able to yield a 
meagre MR contrast. A similar finding was published by Hilger et al. [257] 
that demonstrated only a 20% contrast enhancement at the tumour site 
with a dosage of 20 mg iron particles per kg body weight. The mass 
magnetisation value of the materials used seems to be the dominant 
problem amongst many studies which prevents adequate signal at 
clinically useable dosages. In one study that overcame this problem, Huh 
et al. [258] demonstrated production of magnetite particles which were 
subsequently surface modified with Herceptin® to enable cell specific 
targeting. Although they were able to produce homogenous magnetite 
crystals with a mass magnetisation value of 80 emu/g, this required small 
scale synthesis with several size separation phases to ensure 
homogeneity. In this case the fabrication complexity was the limiting 
factor in moving the material forward into clinical trials.  
1.12.1 Rationale behind this thesis 
With a lack of iron oxide based contrast products available for 
clinical use, there remains a reliance on Gd based agents for many 
contrast applications. As understanding of potential Gd risks develops, 
replacement materials are being sought. This thesis aims to demonstrate 
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that iron oxide can be used as a viable contrast agent capable of 
specifically targeting certain cell lines by using surface coatings to 
overcome the shortcomings of the material. Disadvantages such as 
removal from the circulatory system due to particle size and low 
magnetisation saturation can be overcome by production and surface 
coating techniques, while particle yields can be increased using improved 
production techniques.  
The fabrication of two differing types of iron oxide based contrast 
agents will be investigated with their subsequent performance as an MR 
contrast agent in vitro and in vivo under clinical conditions, examined. The 
applicability of an improved version of this material for targeted cellular 
uptake will also be examined in chapter 4 under the same conditions. 
 
1.13.1 Chapter summary 
This thesis contains 7 chapters which are organised in such a way 
as to first outline the subject area before beginning to discuss the 
experiments and results for the work conducted. Chapter 1 was to serve 
as in overarching introduction to the field and some specifics relating to 
the use of nanoparticles in MR contrast. 
Chapter 2 deals with the underlying principles of the instruments 
used during the characterisation and experimentation phases of the 
investigation. This chapter primarily serves to ensure proper 
71 
 
understanding of the instrumentation so that the reader is able to clearly 
understand the data presented in chapters 3, 4 and 5. 
Chapter 3 presents the fabrication, characterisation and application 
of quasi cubic silica coated iron oxide nanoparticles as an MRI contrast 
agent. this chapter presents this material as an initial investigation into 
the performance of such materials for both biocompatibility and clinical 
MR contrast performance. 
Chapter 4 builds on the materials discussed in chapter 3 and 
investigates the performance of a smaller silica coated iron oxide particle 
for targeted imaging of SKBR3 breast tumours. Again the material is 
characterised and its performance measured under clinical conditions, 
this time targeting the tumour site after intravenous injection. 
Chapter 5 deals with some extensions of the work presented in 
chapters 3 and 4. Induction heating performance of the material 
discussed in chapter 4 is investigated for hyperthermia applications after 
a brief introduction to the field. A DMSA surface coating replacing the 
silica coating of the quasi cubic particles presented in chapter 3 is also 
discussed, along with biocompatibility and MR contrast performance data.  
Chapter 6 simply presents a summary of conclusions drawn based 
on the body of the thesis chapters. While chapter 7 contains an appendix 
of the publications produced during the course of my PhD studies. 
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Chapter 2 
2.1.0 Instrumental apparatus 
 
Precise fabrication of nanomaterials requires a great deal of 
materials characterisation and analysis. In order to properly understand 
the structure and elemental make-up of the particles, many different 
instruments were used to identify certain aspects of the materials as they 
were being fabricated and applied. The following chapter is designed to 
provide a basic understanding of these instruments and their operating 
principles including, transmission electron microscopy (TEM), confocal 
microscopy, X-ray Diffraction (XRD), atomic adsorption spectroscopy 
(AAS), superconducting quantum interference device (SQUID) and 
magnetic resonance imaging (MRI). 
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2.1.1 Electron Microscopy 
Electron microscopy must be employed to visualise surface features 
less than 200 nm in diameter, this being the absolute lower resolution 
limit to light microscopy. Electron microscopes make use of a high voltage 
beam of electrons either passing through or scattering from the sample 
instead of light. The maximum resolution of any microscope is given by 
the equation below, where λ represents the wavelength of the beam (either 
visible light or a high voltage stream of electrons) and (alpha) signifies one-
half of the angular aperture. As a high voltage electron beam has a 
wavelength in the range of a few Angstroms, an electron microscope can 
in theory resolve images down to the atomic level, however in common 
practice 1-0.5 nm is considered easily achievable. 
 
  
    
     
 
 
2.1.2 Transmission Electron Microscopy 
TEM is an electron microscopy technique that allows for thin 
samples to be observed on a 2D plane by passing an accelerated electron 
beam through a sample supported on a carbon film on a copper mesh. At 
lower resolution the image produced simply provides contrast between 
densities in the sample material as electron adsorption increases with 
increasing density, this yields contrast on a phosphorescent plate at the 
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end of the microscope column. The contrast is a direct result of the beam 
interacting with the different elements within the sample as their 
scattering potentials vary. The scattering potentials for different elements 
can be inferred from the Rutherford formula shown below, where (K) is the 
deflection potential, (r) is the distance between the electron and the 
nucleus, (z) the positive charge and (e) the electron charge. This equation 
demonstrates the relationship between scattering potential and atomic 
number, as one increases so does the other, leading to the clear contrast 
between materials under TEM.  
  
     
  
 
Several types of TEM were used to capture images presented in this 
thesis, a JEOL 2010 high resolution transmission electron (HRTEM) 
microscope operated at an accelerating voltage of 200 kV and JEOL 1010 
TEM microscope with an operating voltage of 100 kV.  
 
2.1.3 X-Ray Diffraction  
In this thesis XRD was used to determine the crystalline type and 
nature of various metals and metal oxides. In most cases the samples 
were in powder form, which consisted of many randomly oriented grains of 
sample. The instrument uses the elastic scattering of X-rays with a 
wavelength of 0.1 Angstroms to produce diffraction patterns 
representative of the atomic configuration within the sample. The X-ray 
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beam primarily interacts with the electrons within the target, this 
interaction, when occurring at the correct angle, causes X-ray photons to 
be elastically deflected. These X-rays are picked up by a detector and the 
required angle and number of detected photons is recorded. In crystalline 
materials, the atoms are arranged in periodic patterns and will produce 
regular scattering patterns in the form of concentric rings. The spacing 
and intensity of these rings can be mapped out to form a fingerprint of a 
particular crystal configuration of the element. 
These diffraction patterns reveal the distribution of the atoms within 
the sample and their arrangement relative to each other. When the atoms 
are arranged regularly, as they are in crystalline materials, the scattered 
photons can constructively interfere, producing sharp interference 
maxima. The Bragg equation (shown below) is generally used to relate the 
aspects of X-ray diffraction, where n represents the order of diffraction, λ 
is the wavelength of the X-rays, d the interplanar spacing and θ denotes 
the scattering angle. 
           
All the XRD patterns displayed in this thesis were obtained using a 
Bruker D8 ADVANCE X-Ray diffractometer, fitted with a graphite-
monochromated copper tube source (Cu Kα radiation, λ = 1.5406 Å) and a 
scintillation counter detector.  
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2.1.4 Atomic Absorption Spectroscopy (AAS) 
AAS is generally used as a quantitative technique for measuring an 
analyte concentration within a sample. The basic principle of the 
technique relies on the sample being atomised, typically by an air-
acetylene flame and then subjected to a well-defined quantity of element 
specific radiation. The wavelength of the radiation is chosen specifically 
for the element under scrutiny due to the required electron transition 
energies of each element; this is what gives this technique its selectivity. 
The measured absorbance of radiation for the sample must be compared 
to a series of samples of known concentration to create a calibration curve 
and as such relates to the Beer-Lambert law shown below, where A is the 
measured absorbance, a(λ) is the absorptivity coefficient, b is the path 
length and c is the analyte concentration. 
           
The Beer-Lambert law cannot completely describe the experimental 
results given that nonuniformity within the sample, scattering of light 
from particles, shifts in chemical equilibria and refraction index as a 
function of concentration adversely affect the outcomes. This is why a 
calibration curve is required for direct comparison of absorbance readings 
of the unknown analyte compared to known concentrations. In this thesis 
AAS is used to determine the concentration of Fe present in samples and 
to allow adjustment of particle concentration to known quantities prior to 
experiments. The AAS instrument used was a Varian AA280FS Fast 
Sequential Atomic Absorption Spectrometer.  
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2.1.5 Magnetic Resonance Imaging  
MRI is regarded as a powerful imaging tool because of its high 
spatial resolution capability, non-invasive nature and its capability to 
avoid ionizing radiation. This technique is able to exploit nuclear magnetic 
resonance (NMR) principles to produce cross sectional images of a living 
organism, the basic process is outlined in the below diagram. In general, 
MRI scanners are tuned to effect water protons within the tissues of the 
subject, prior to being placed in the strong uniform magnetic field of the 
scanner, the magnetic moments of the water protons are randomly 
oriented with respect to each other (Figure 1 panel 1). Once placed inside 
the magnetic field, these magnetic moments align with the applied field 
axis in one of two orientations (Figure 1 panel 2). A very finely tuned 
polarised radio frequency (RF) pulse is then applied to the protons, this 
pulse is precisely tuned to resonate with only the water protons, this 
pulse contributes enough energy to the protons to force a spin transition 
away from the alignment of the applied magnetic field (Figure 1 panel 3). 
The water protons then decay from this excited state and re-align their 
magnetic moments with the applied external field, this process re-emits 
RF radiation which is detected by the scanner and interpreted into an 
image based on the time taken for the protons to relax to the ground state 
(Figure 1 panel 4).  
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Figure 1: Magnetic excitation cycle of water protons to produce an MR contrast image. 
 
In order to form a coherent image, the relative position of each 
emitted signal must be deciphered. This is accomplished by applying an 
additional gradient field across the sample which makes the magnetic field 
strength vary based on position within the target. This translates into a 
predictable change in emitted radio frequency from the protons 
comparative to their position and their relative location can be obtained 
using inverse Fourier transformation. MRI experiments undertaken within 
this thesis were completed on a on a 3.0 Tesla clinical Siemens Trio MRI 
scanner using a 12-channel head coil and the following parameters: T2-
weighted imaging, spin echo sequence, transverse orientation, echo time 
(TE) = 76 ms, repetition time (TR) = 2000 ms, matrix 320x320, slice 
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thickness= 1.70mm. Specific scanning protocols will be mentioned as the 
relevant experiments are discussed. 
 
2.1.6 Confocal microscopy 
Confocal microscopy takes its name from the fact that there are two 
focal points, one on each of the illumination and detection light paths. 
Typically mixes of krypton/argon and helium/neon gas lasers are used to 
produce a range of very specific wavelengths to be sent down the 
excitation light path. After passing through the first pinhole to remove out 
of focus light the light is reflected off a beam splitter and sent to the 
objective lens. In fluorescence microscopy this beam splitter is replaced by 
a dichromic filter which reflects only certain wavelengths. On the return 
path the emitted light passes through the beam splitter or dichromic filter, 
and passes through the final pinhole before the detector to remove 
unfocused light.  
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Figure 2: Confocal microscope arrangement, image courtesy of Dirk Butcher from The 
Marder Lab [1] 
 
This pinhole setup allows for high resolution imaging of a very thin 
focal plane within the sample and much sharper imaging of fluorescence 
within samples due to the removal of out of focus light. In this thesis 
confocal microscopy is used to image the interaction of human cells with 
nanomaterials and the instrument used was a Nikon A1 Confocal 
microscope. 
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2.1.7 Superconducting Quantum Interference 
Device (SQUID) 
SQUID is a highly sensitive technique used to measure magnetic 
fields and can quantify the magnetic properties of a material. It operates 
by measuring the difference in the voltage across a superconducting loop 
broken by either 2 (DC) or 1 (RF) Josephson junctions. These junctions 
are formed by either a thin insulating layer or constriction between two 
identical superconductors. Essentially, each superconductor has 
associated with it an arbitrary phase θ, while two weakly connected 
superconductors the phase is equal to δ = θ1 – θ2. This results in a phase 
difference between the junctions given the bias current that is passing 
through each side of the loop. This electrical behaviour is exceptionally 
stable as the flux loop can only maintain flux in multiples of the flux 
quantum and if an external flux is applied, an observable voltage change 
between the junctions occurs. In this way, if a material with magnetic 
properties is placed inside the ring, and a known external field is applied, 
the magnetic flux of the sample can be inferred by the difference to the 
expected voltage between the junctions at known magnetic flux input. 
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Figure 3: Schematic of the superconducting loop and Josephson Junctions in a DC 
SQUID magnetometer. 
 
SQUID is an exceptionally sensitive technique, so sensitive in fact it 
is able to measure the magnetic fields produced by biological systems. 
However the superconducting property of the loops requires that they 
operate at exceptionally low temperatures, some as low as 2 K, and 
require a liquid helium bath to operate. In this thesis SQUID is used to 
quantify the magnetic properties of magnetite nanoparticles, the model 
used was a Quantum Design MPMS-XL5 operating at 4K. 
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Chapter 3 
3.1.0 Silica coated quasi cubic magnetite as a 
T2 contrast agent 
 
This chapter presents and discusses the fabrication, 
characterisation and application of quasi cubic particles produced by 
thermal decomposition. The particles were characterised by TEM, XRD 
and SQUID before having their biocompatibility and cell uptake compared. 
The quasi cubic particles were then applied as a contrast agent for MR 
imaging under clinical conditions.  
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3.1.1 Introduction  
The following chapter documents the fabrication and 
characterisation of silica coated magnetite nanoparticle for use as T2-
weighted MRI contrast agents. The production methodologies and 
materials characterisation regarding structure, cytotoxicity, particle 
stability and relaxivity will be discussed, as will in vivo, in vitro 
applications.  
The initial goal was to produce a magnetite@silica (@ denotes a 
―magnetite core-silica shell‖ structure) with a total diameter of less than 
100 nm, along with good particle stability, high production yield, high 
magnetisation saturation and low cyto-toxicity. As previously discussed in 
section 1.6.5, it was determined that the thermal decomposition method 
proposed by Park et al. [1] was the most promising magnetite fabrication 
technique; based on the high yield, magnetisation and size monodispersity 
parameters.  
The main drawback of this method is the hydrophobicity of the 
resulting particles, this was to be overcome by the addition of a silica 
coating based on the Stöber process [2], similar to that presented by Fang 
et al. [3]. This silica coating process was chosen for its ease of large batch 
production, particle stability and availability of attachment sites for later 
modification with targeting molecules. This chapter discusses both silica 
coated and uncoated particles and will denote the coated particles as 
―Mag@SiO2‖ and the uncoated simply as ―Mag‖. 
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3.2.1 Materials and methods 
All chemicals were purchased from Sigma-Aldrich and used as 
received without further modification. The prostate cancer cells (PC3 cell 
line) were purchased from American Type Culture Collection (ATCC). 
CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega) kit 
was purchased from Promega Corporation. 
 
3.2.2 Synthesis of iron oxide nanoparticles 
The process used to fabricate the magnetic nanoparticles for use in 
this study was thermal decomposition of organic iron precursors as 
reported by Park et al. [1] with significant modification. The iron-oleate 
compound was synthesised by dissolving 5.4 g iron chloride and 18.25 g 
sodium oleate in a solution of 70 ml hexane, 40 ml ethanol and 30 ml 
distilled water. The solution was homogenised, then refluxed at 70 °C for 4 
hours, then the organic layer containing the iron-oleate complex was 
separated and washed with 30 ml distilled water in a separating funnel. 
All remaining solvent was removed from the compound by heating in an 
oven overnight at 100 °C, leaving the waxy iron-oleate residue behind. 9 g 
(1.42 Mol) of the iron-oleate was then dissolved in 63.3 ml 1-octadecene 
and refluxed under nitrogen at 320 °C in the presence of 1.425 g oleic acid 
as a capping agent. After aging at 320 °C for 30 min, the solution was 
allowed to cool to room temperature. To precipitate the magnetite 
particles, 250 ml ethanol was added to the black mixture and sonicated 
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for 30 minutes. The particles were centrifuged out of solution and were 
collected and washed 3 times in ether and ethanol. All solvent was then 
removed and the particles were allowed to dry under a flow of nitrogen to 
yield the magnetite as a dry powder. 
 
3.2.3 Silica shell formation process 
Silica-coated iron oxide nanoparticles (Mag@SiO2) were prepared 
using a method significantly modified from Fang et al and Morel et al [3, 4] 
wherein controlled hydrolysis of silica precursor in the presence of 
magnetite nanoparticles was performed. In the present approach, pre-
formed magnetic particles were used as nucleating sites for subsequent 
hydrolysis of silica precursor around them. In our process, the particles 
were first stabilised using a layer of citric acid by refluxing the particles in 
ethanol and 2 ml solution of 5 mg/ml trisodium citrate for 6 hours. The 
resulting particles were then washed twice in water and then redispersed 
in 15 ml ethanol. To this solution 2 mL deionized water (MilliQ) and 1 mL 
of ammonia (25% solution) was added while immersed in a sonicator 
programmed to switch on for 1 in every 10 min. Further, an overhead 
stirrer was used to mix the solution while 4 mL of 1:60 (TEOS : ethanol) 
was added at the rate of 0.4 ml/h using a syringe pump. The coating 
process was allowed to continue for 12 hours at room temperature. The 
silica coated iron oxide nanoparticles were centrifuged, washed three 
times with ethanol and redispersed in MilliQ-water. 
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3.3.1 Characterisation 
The relevant XRD, TEM and SQUID instrumentation information 
has been previously discussed in chapter 2. The following pertains to 
certain instruments or procedures that may have a large variation in their 
conditions of use which need to be specified for appropriate comparison.  
 
3.3.2 T2 relaxation  
The T2 relaxation was investigated by first preparing solutions of 
the magnetic particles with increasing concentration, from 10 to 100 
µg/mL of particles in MilliQ-water. The solutions (1mL) were then scanned 
in triplicate, using Milli-Q water as a control. Scanning was undertaken 
on a clinical 3.0 T Siemens Trio MRI scanner, fitted with a 12 channel 
head coil. T2 relaxation was determined using a single echo sequence (SE) 
and constant repetition times (TR) of 200 ms, and multiple echo times (TE) 
ranging between 0.99 – 100 ms. The signal was fitted to the established 
mono-exponential expression by plotting as a function of TE. The T2 rate 
was calculated by plotting the reciprocal of the relaxation rate at a TE 
value of 10.86 ms. This was a function of the relative molar iron 
concentration as measured by AAS, the T2 value was calculated by linear 
regression of the slope of this line. The T2 values used are averages 
calculated from experiments in triplicate with error calculated as standard 
error of the mean. 
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3.3.3 Cell uptake 
Human prostate cancer cells (PC3 cell line) were routinely cultured 
at 37°C in a humidified atmosphere with 5% CO2 using RPMI 1640 
medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin, 
1% streptomycin/penicillin and 1 mM L-glutamine. For sub-culturing, 
PC3 prostate cancer cells were detached by washing with phosphate 
buffered saline (PBS) and incubating with trypsin-EDTA solution (0.25% 
trypsin, 1 mM EDTA) for 5 min at 37°C, followed by washing and 
incubation with supplemented RPMI 1641 medium. For cell uptake, the 
cells were first seeded in 24-well polystyrene dishes for 24 h, followed by 
incubation with nanoparticles for 24 h at 37°C in complete cell media, and 
subsequent three times washing of cells with PBS, before imaging under 
an inverted microscope. For cytotoxicity assays, the viability of PC3 
prostate cancer cells exposed to Mag@SiO2 nanoparticles in the absence of 
cell growth medium was determined. A CellTiter 96 AQueous One Solution 
Cell Proliferation Assay (Promega) kit containing the tetrazolium 
compound 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS), was used to monitor cell viability 
according to the manufacturer's protocols. MTS colour change was 
monitored using a plate reader at 490 nm, and cell viability data was 
plotted by considering the viability for the untreated cells as 100%. 
Experiments were performed in triplicates, and error bars represent 
standard experimental errors. 
 
105 
 
3.3.4 MRI study 
MRI studies were performed for nanoparticle solutions stored in 
phantoms, in PC3 prostate cancer cells after nanoparticle uptake, and in 
a mouse model with breast cancer. For phantom MRI studies, phantoms 
were prepared in Eppendorf tubes with Mag@SiO2 nanoparticles at three 
different Fe concentrations (0.18 mM, 0.9 mM, 1.79 mM) and a saline 
solution without any nanoparticles was used as a control. For in vitro MRI 
studies, PC3 cancer cells were cultured using the above protocol in 24 
well polystyrene plates, and incubated for 24 h with Mag and Mag@SiO2 
nanoparticles at three different concentrations (0.18 mM, 0.9 mM, 1.79 
mM) and a control with cells but no nanoparticles. MRI measurements for 
phantoms and PC3 cells were performed with a clinical 3.0 Tesla Clinical 
Siemens Trio MRI scanner using a 12-channel head coil and the following 
parameters: T2-weighted imaging, gradient echo sequence, multiple echo 
time (TE) ranging from 0.99–100 ms, repetition time (TR) = 200 ms, matrix 
128×128, slice thickness of 3 mm.  
Relaxation rates (R2) were determined by using a single echo 
sequence (SE) with a constant TR of 200 ms and multiple TE ranging from 
0.99–100 ms. The signal was plotted as a function of echo time and fitted 
to obtain the R2 values. The R2 values of the Mag@SiO2 in phantoms and 
PC3 cells were determined by plotting the relaxivity at a TE of 10.86 ms, 
as a function of molar iron concentration in respective samples, and 
extracting the T2 value from the slope by linear regression of data points 
obtained at lower Fe concentration values.  
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Only lower Fe concentrations were used to determine the T2 values, 
because with increasing Fe concentrations above a particular threshold, 
the MR signals tend to lose their linearity. For the in vitro MRI 
measurements in phantoms and PC3 cells, enhancement of the R2 signal 
within the PC3 cells was calculated by: 
   
          
      
Where R2 is the average of triplicate scans read directly from the scanner. 
For in vivo MRI experiments, breast tumour bearing mice were 
developed in-house, anaesthetised with ketamine (80 mg/kg body weight) 
and xylazine (5 mg/kg body weight), and placed within the 12-channel 
head coil. Images were acquired before and after injection of 100 µL of 
Mag@SiO2 particles suspension of 100 µg/mL concentration in saline 
locally at the tumour site. A T2-weighted spin echo sequence was acquired 
with TE/TR of 60/200 ms, a slice thickness of 3 mm and a 128x128 
matrix. Data analysis was performed manually by placing ROIs in tumour 
and tissue areas on the images. It is important to note that all MR 
measurements were undertaken in a clinical scanner under guidance and 
supervision of technicians from the Peter MacCallum Cancer Research 
Centre. As such this data represents clinically obtained data as all 
imaging parameters were constrained to those of clinical facilities.  
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3.4.1 Results and discussion 
TEM analysis of the pristine and silica coated magnetic 
nanoparticles is shown in Figure 1. The overall morphology of the particles 
produced was polydisperse and quasi-cubic; however the synthesis 
method did yield gram quantities of particles ranging from 40-50 nm in 
diameter in a single batch. From the TEM images it is possible to 
determine internal material boundaries within the individual quasi-cubes, 
this leads us to the possibility that the quasi-cubes formed as a result of 
aggregation of several smaller spherical particles late in the growth 
process. Due to the novel morphology of the particles produced it was 
decided to continue characterisation of the material for the MR contrast 
application despite the polydispersity of the product. 
The shelf life of commercially available MRI contrast agents is in fact 
one of the major limitations associated with clinical applicability of such 
materials. Previously, silica shell coatings have demonstrated increased 
biocompatibility and particle stability, as well as a facile surface for 
further bio-functionalisation in different nanomaterials [5-7]. Therefore, to 
provide chemical stability to these quasi cubic magnetic nanoparticles, a 
silica shell was grown around quasi-cubic magnetite particles (within 3 
days of their synthesis), thereby producing core-shell, magnetite-silica, 
nanoparticles Figure 1b.  
The controlled silica coating of Mag nanoparticles led to formation of 
Mag@SiO2 core-shell structures with an approximately 20 nm silica shell 
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around a 45 nm quasi-cubic magnetite nanoparticle (Figure 1 and inset). 
Low magnification TEM analysis of Mag@SiO2 core-shell structures 
indicated that most of the magnetite nanoparticles retained their quasi-
cubic morphology after silica coating, and more than 75% of particles in 
the sample were found to be individually coated with a silica shell. 
However, less than 25% of structures consisted of either two or three or 
no Mag particles within the silica shell. Notably, this type of particle 
distribution is typical of a chemical synthesis route, which is not 
necessarily always explicitly acknowledged in the prevailing literature. 
Additionally, we observed that after coating Mag nanoparticles with silica, 
the Mag@SiO2 particles remained stable in phosphate buffer saline (PBS) 
solution up to 1 mg/mL concentration, as well as in the readily-
dispersible powder form for at least up to 6 months. The TEM image 
shown in Figure 1 was acquired after 6 months of storage of Mag@SiO2 
nanoparticles at room temperature and was similar to those imaged 
immediately after synthesis. This suggests that a silica coating over Mag 
nanoparticles can significantly improve their stability for long-term 
storage conditions, thus retaining their medical properties by improving 
their shelf life. This is one of the crucial parameters for developing MRI-
based contrast agents for clinical and commercial applications.  
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Figure 1: TEM images of the synthesised Mag particles (A) and (B) Mag@SiO2 particles 
demonstrating their size and distribution are shown.  
 
3.4.2 XRD 
The particles produced by the thermal decomposition method were 
examined under XRD and the resulting patterns are displayed in Figure 2. 
The pattern produced, fitted well with the JCPDS card file for Fe3O4 
magnetite (card file number 75-0449) and is typical of spinel phases of 
iron oxide. Although it is difficult to rule out the presence of maghemite 
from XRD analysis, given the similarity of the diffraction patterns, there 
was no dominance of 221, 203 or 116 peaks in the sample that would 
indicate the presence of a large amount of maghemite within the product. 
Although it is expected that some maghemite and hematite would have 
been present simply due to post fabrication oxidation, however the 
functional mass of the product was determined to be magnetite from the 
XRD analysis. 
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Figure 2 XRD patterns of the as synthesised magnetite (Mag) and silica coated magnetite 
(Mag@SiO2) particles 
 
Figure 2 also demonstrates the XRD pattern obtained from the 
sample after silica coating. Due to the surface of the magnetite being 
coated in approximately 20 nm of silica, less of the magnetite signal was 
obtained, however the (311) and (440) major peaks were still visible. An 
additional peak was observed at 29.1° 2θ in the sample coated with silica, 
this peak may be attributed to a β-magnetite silica mixed phase (220) that 
formed at the boundary between the core and shell structures (JSPDS file 
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no 73-0963). The silica coating only adds a few low angle amorphous 
humps to the spectra and an overall dampening of signal intensity from 
the magnetite. 
 
3.4.3 SQUID 
To fulfil the requirements of an MR contrast agent it was essential 
for the material to exhibit a high net magnetisation value. To determine 
the magnetic susceptibility of the Mag@SiO2, the material was analysed 
using a SQUID magnetometer. The curve in Figure 3 illustrates the 
magnetic behaviour exhibited by the Mag@SiO2, which reaches a 
maximum value of 74.4 emu g-1, that is comparable to the commercially 
available Resovist [8]. The curve also shows low hysteresis and 
remanence, suggesting a predominantly superparamagnetic behaviour. 
With the high emu value and superparamagnetic nature, it was expected 
that the material would produce good contrast during the MR imaging 
process. 
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Figure 3: SQUID measurement of the as synthesised magnetite particles. The value 
shown is the saturation magnetisation of the Mag@SiO2 particles in emu/g at 4 Kelvin. 
The insert displays a magnification of the central axis. 
 
3.4.4 Cell uptake 
A cell uptake study was undertaken using human prostate cancer 
PC3 cells to determine the comparative ability of the uncoated Mag 
particles and the Mag@SiO2 to be internalised by human cells (Figure 4). 
Both the Mag@SiO2 and Mag particles were incubated with PC3 cells for 
24 hours at a concentration of 50 µg/ml. When PC3 cells were exposed to 
Mag nanoparticles, it was observed that bare Mag nanoparticles tended to 
form large aggregates (of dimensions similar to cell size) over a 24 h 
exposure period; which restricted their ability to be internalised by PC3 
cells (Figure 4B). As can be inferred from Figure 4B, these large clusters of 
bare Mag nanoparticles predominantly attach to the exterior of the cells, 
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and are difficult to be internalized by PC3 prostate cancer cells. 
Conversely, after SiO2 coating, Mag@SiO2 nanoparticles remain well-
dispersed in the solution even after 24 h, which facilitates their more 
efficient uptake by PC3 cells, as can be seen from a higher density of 
Mag@SiO2 nanoparticles inside PC3 prostate cancer cells (Figure 4C).  
Our group and others have previously demonstrated that 
nanoparticle size and aggregation in biological media can play a crucial 
role in cellular uptake processes, as non-specific uptake of sub-100 nm 
nanoparticles is generally observed via endocytosis mechanism of the cells 
[9-14]. Aggregation of Mag nanoparticles in biological media, and 
subsequent aggregation reduction after silica coating, clearly suggests the 
advantage of Mag@SiO2 core-shell nanoparticles over bare Mag 
nanoparticles for biological applications. Based on results from cell uptake 
studies, bare Mag nanoparticles were found to be unsuitable for biological 
applications due to aggregation. Therefore only Mag@SiO2 nanoparticles 
were chosen for further studies regarding their suitability for MRI 
applications. 
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Figure 4: Optical microscopy images of PC3 human prostate cancer cells (control) grown 
for 24 h. (A) in the absence of nanoparticles (control), and in the presence of (B) Mag and 
(C) Mag@SiO2 nanoparticles followed by three washings with PBS. Scale bar 50 µm. 
 
3.4.5 Cytotoxicity 
Before exploring any further MR applications of the Mag@SiO2 
nanoparticles, biocompatibility profiling of these particles was 
accomplished using an in vitro MTS-based cytotoxicity assay (Figure 5), 
which is a common procedure for biocompatibility analysis [15]. Particle 
uptake was then correlated to the relative cytotoxicity to PC3 cells across 
increasing particle concentrations ranging from 1-100 µg/ml. As an 
internal control, the MTS assay was run with mirrored concentrations of 
nanoparticles and MTS dye without cells. The reduction of the dye caused 
by nanoparticles without cell media was subtracted from data to ensure 
the viability measurements were not false positives and set a baseline for 
each individual concentration. Previous studies indicate that iron oxide 
nanoparticles show negligible toxicity at lower concentrations but can be 
mildly toxic at higher concentrations. [16-19] It is evident from Figure 
5 that Mag@SiO2 nanoparticles did not significantly affect PC3 cell 
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viability up to concentrations of 50 µg/mL, where greater than 80% cell 
viability was still maintained. However, further increases in particle 
concentration equivalent to 100 µg/ml Fe resulted in a cell viability loss of 
up to 30%. This suggests the Mag@SiO2 nanoparticles may be suitable for 
MRI applications if the administered dosage is below that which induces 
toxicity, yet is still able to produce significant contrast during imaging. 
However, this aspect may require further detailed investigation, wherein 
the effect of Mag@SiO2 nanoparticles on cytokine production profile of 
cells will need to be investigated. 
 
 
Figure 5: Biocompatibility of Mag@SiO2 nanoparticles assessed using MTS assay after 
their exposure to PC3 cancer cells for 24 h with respect to different Fe concentration in 
Mag@SiO2 nanoparticles. 
 
3.4.6 Relaxivity 
Relaxivity is a measure of the efficiency of a MR contrast agent to 
enhance the proton relaxation rate and increase the efficiency to which 
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image contrast is produced during MRI [20]. The relaxivity of the 
Mag@SiO2 was assessed on a 3 Tesla clinical MRI scanner to measure its 
performance as a T2 MR contrast agent. The relaxivity measurements 
were performed both on nanoparticles as suspension in phantoms, as well 
as after being internalised by PC3 prostate cancer cells. Mag@SiO2 
nanoparticles were found to have a high relaxivity value of 263.23 
L/mmol/s in cell free suspensions, and 230.90 L/mmol/s after uptake by 
PC3 cells. Having a high relaxivity value along with high mass 
magnetisation values are important considerations when developing T2 
contrast agents. This is due to the spin-spin relaxation process of protons 
in water molecules surrounding the nanoparticles, being facilitated by the 
large magnitude of magnetic spins from within the nanoparticles [21, 22]. 
Mag@SiO2 nanoparticles with high mass magnetization and high relaxivity 
values may therefore result in strong T2-weighted MR signal intensity 
decreases as measured by MRI [23]. This is critical in allowing nanomolar 
activity of contrast agents, which will reduce the overall required contrast 
agent dose to the patients.  
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Figure 6: Evaluation of Mag@SiO2 nanoparticles as a T2 MR contrast agent is shown in 
the form of % signal enhancement with increasing concentration of Fe. A) demonstrates 
performance in a phantom studies compared to a pure saline control; while B) presents 
results obtained after uptake by PC3 cells. 
 
The relaxivity data in Figure 6 also suggests a reduction in the 
relaxivity value of Mag@SiO2 nanoparticles in PC3 cells after cellular 
uptake compared with that in suspension. This finding corroborates well 
with previous studies, which showed that the relaxivities of native iron 
oxide nanoparticles were higher compared to those after accumulation in 
the cells [24, 25]. The mechanisms responsible for this effect have not yet 
been fully understood, however it may possibly be attributed to the 
confinement of nanoparticles within endosomes of the target cells. This 
might cause a build-up of magnetic field inhomogeneity after sub-cellular 
compartmentalization, which would conversely be absent in uniformly 
distributed nanoparticles in suspensions [26]. 
Additionally, the different geometrical arrangement of nanoparticles 
in suspensions vs. that which occurs in cells may alter antiferromagnetic 
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coupling as a result of clustering within the sub-cellular compartments 
and may play some further role in reducing relaxivity values after cellular 
uptake [6, 26]. There is also some expected loss of particles as not all the 
Mag@SiO2 is taken into the cells prior to being washed, resulting in a 
lower signal. 
In comparison to the relaxivity values of 230–269 L/mmol/s 
observed for Mag@SiO2 nanoparticles in this study, the commercial 
Resovist nanoparticle contrast agent has been reported to have a lower 
value of 151 L/mmol/s [8]. The observed relaxivity value of Mag@SiO2 
nanoparticles prepared in this study is also higher than those reported for 
undoped magnetite particles (218 L/mmol/s) in recent detailed studies 
[27]. For doped magnetic particles, it has been reported that high 
relaxivities of up to 358 L/mmol/s can be achieved by doping magnetite 
with Mn (MnFe2O4) [28]. However, potential leaching of Mn during 
administration of these MR contrast agents in the body might pose 
cytotoxicity issues [19] and to the best of my knowledge, the author was 
the first to report undoped Mag@SiO2 nanoparticles with such high 
relaxivity values in literature [29].  
In addition, the relaxivity studies performed as a function of 
different concentrations of Fe in Mag@SiO2 nanoparticles, both as a 
suspension in phantoms Figure 6 (A), and after 24 h of nanoparticle 
uptake by PC3 prostate cancer cells Figure 6 (B); revealed that the 
Mag@SiO2 nanoparticles act as excellent T2-weighted contrast agents. 
This contrast value is visualised by an image darkening effect, 
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demonstrated by drop in R2 ( 
   
          
 ) signal intensity with increasing Fe 
concentrations. This is clearly visible in Figure 6 when comparing the 100 
µg/mL Fe concentration to the 50 µg/ml. Under these conditions the 
Mag@SiO2 nanoparticles provide a signal enhancement of ∼90% in 
comparison to more than 70% signal enhancement during imaging of PC3 
prostate cancer cells. This is considered significant signal enhancement in 
comparison to most of the previously reported materials, in which 
generally only 15–20% signal enhancement has been observed [6]. Such 
strong MR signal enhancement is expected from Mag@SiO2 nanoparticles 
because of their relatively high relaxivity and saturation magnetization 
values. 
 
3.4.7 Tissue imaging 
The Mag@SiO2 particles had demonstrated biocompatibility and 
excellent T2 contrast production in both phantom and cell MR studies, 
however performance under these conditions is rarely comparable to that 
which occurs in vivo. To investigate the performance of the Mag@SiO2 
under such conditions, 10 µg of Mag@SiO2 particles were injected directly 
into a breast tumour site of a nude mouse and imaged on the same 
clinical 3 Tesla scanner. The images in Figure 7 illustrate the contrast 
achieved within tissue directly at the site of injection compared to the 
surrounding tissue. This final experiment demonstrates the ability for 
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Mag@SiO2 nanoparticles to effectively operate as a T2 weighted MR 
contrast agent within tissue.  
 
 
Figure 7: T2-weighted MR images of nude mice with breast tumour obtained (A) before 
and (B) after injection of MR contrast agent, obtained using a 3 Tesla MR scanner. 
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3.5.1 Conclusion 
There are many important factors that must be considered when 
developing an MR contrast agent and the Mag@SiO2 nanoparticles 
fabricated in this initial study have successfully addressed a majority of 
them. The core magnetite nanoparticles possess both high net 
magnetisation values along with superparamagnetic behaviour; and are 
capable of being fabricated in batches large enough to be viable for clinical 
applications. 
The addition of the silica coating rendered the particle stable in 
water, reduced aggregation, and cause little cytotoxicity within the clinical 
dosage range required to elicit a contrast response. In this study, a facile, 
large-scale synthesis of quasi-cubic magnetite and Mag@SiO2 
nanoparticles of sub-100 nm size has been demonstrated. The Mag@SiO2 
nanoparticles reported here have a shelf life of more than 6 months, and 
are efficiently internalised by human cells without causing significant 
aggregation or cellular toxicity.  
The biological half-life of smaller silica-coated iron oxide 
nanoparticles (>60 nm) is expected to be further increased due to their 
reduced interaction with the body fluids. This study therefore clearly 
underlines the importance of SiO2 coating towards improving the uptake 
of Mag@SiO2 nanoparticles by PC3 prostate cancer cells and improving 
the shelf life of MR contrast agents. The Mag@SiO2 nanoparticles act as 
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promising T2 contrast agents offering a potentially viable option as a 
commercial MR contrast agent.  
This is attributable to their small size, high MR signal 
enhancement, relative biocompatibility, longer shelf life, and highly 
modifiable silica surface chemistry which will allow the adhesion of 
multiple molecular markers for targeted MRI in further studies discussed 
in chapter 4. These characteristics of a T2 contrast agent are highly 
desirable for magnetic resonance imaging applications at the pre-clinical 
level and for later use clinically. Given the success of this material 
towards its application, further modifications to both the structure and 
surface coating have been investigated for application towards targeted 
MR contrast using cell specific targeting molecules. This application and 
the experimental results are discussed in the following chapter. 
The work described in this chapter was reviewed and subsequently 
published in PLOS 1 under the title ―Quasi-cubic magnetite/silica core-
shell nanoparticles as enhanced MRI contrast agents for cancer imaging‖ 
[29] 
  
123 
 
3.6.1 References 
1. Park J, An KJ, Hwang YS, Park JG, Noh HJ, Kim JY, et al. Ultra-large-scale 
syntheses of monodisperse nanocrystals. Nature Materials 2004,3:891-895. 
2. Stober W, Fink A, Bohn E. Controlled growth of monodisperse silica spheres in 
micron size range. Journal of Colloid and Interface Science 1968,26:62-&. 
3. Fang CL, Qian K, Zhu JH, Wang SB, Lv XX, Yu SH. Monodisperse alpha-
Fe(2)O(3)@SiO(2)@Au core/shell nanocomposite spheres: synthesis, 
characterization and properties. Nanotechnology 2008,19. 
4. Morel AL, Nikitenko SI, Gionnet K, Wattiaux A, Lai-Kee-Him J, Labrugere C, et al. 
Sonochemical approach to the synthesis of Fe3O4@SiO2 core-shell nanoparticles 
with tunable properties. Acs Nano 2008,2:847-856. 
5. Bardhan R, Chen WX, Perez-Torres C, Bartels M, Huschka RM, Zhao LL, et al. 
Nanoshells with Targeted Simultaneous Enhancement of Magnetic and Optical 
Imaging and Photothermal Therapeutic Response. Advanced Functional Materials 
2009,19:3901-3909. 
6. Hilger I, Trost R, Reichenbach JR, Linss W, Lisy MR, Berndt A, et al. MR imaging 
of Her-2/neu protein using magnetic nanoparticles. Nanotechnology 2007,18. 
7. Goloverda G, Jackson B, Kidd C, Kolesnichenko V. Synthesis of ultrasmall 
magnetic iron oxide nanoparticles and study of their colloid and surface 
chemistry. Journal of Magnetism and Magnetic Materials 2009,321:1372-1376. 
8. Vogl TJ, Schwarz W, Blume S, Pietsch M, Shamsi K, Franz M, et al. Preoperative 
evaluation of malignant liver tumors: comparison of unenhanced and SPIO 
(Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US. 
European Radiology 2003,13:262-272. 
9. Ohmori M, Matijevic E. Preparation and properties of uniform coated inorganic 
colloidal particles .8. silica on iron. Journal of Colloid and Interface Science 
1993,160:288-292. 
10. Ohmori M, Matijevic E. Preparation and properties of uniform coated colloidal 
particles .7. silica on hematite. Journal of Colloid and Interface Science 
1992,150:594-598. 
11. Murakami Y, Kenjo A, Sadoh T, Yoshitake T, Miyao M. Solid-phase crystallization 
of beta-FeSi2 thin film in Fe/Si structure. Thin Solid Films 2004,461:68-71. 
12. Walkey CD, Olsen JB, Guo H, Emili A, Chan WCW. Nanoparticle Size and Surface 
Chemistry Determine Serum Protein Adsorption and Macrophage Uptake. Journal 
of the American Chemical Society, 2012. 134(4): p. 2139-2147. 
13. Florez, Herrmann C, Cramer JM, Hauser CP, Koynov K, Landfester K, et al., How 
Shape Influences Uptake: Interactions of Anisotropic Polymer Nanoparticles and 
Human Mesenchymal Stem Cells. Small, 2012. 8(14): p. 2222-2230. 
14. Albanese A, Tang PS, Chan WCW. The Effect of Nanoparticle Size, Shape, and 
Surface Chemistry on Biological Systems, in Annual Review of Biomedical 
Engineering, Vol 14, M.L. Yarmush, Editor. 2012. p. 1-16. 
15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application 
to proliferation and cytotoxicity assays. Journal of Immunological Methods 
1983,65:55-63. 
16. Alberola AP, Radler JO. The defined presentation of nanoparticles to cells and 
their surface controlled uptake. Biomaterials 2009,30:3766-3770. 
17. Nel A, Xia T, Madler L, Li N. Toxic potential of materials at the nanolevel. Science 
2006,311:622-627. 
18. Prina-Mello A, Crosbie-Staunton K, Salas G, Puerto MM, Volkov Y. 
Multiparametric Toxicity Evaluation of SPIONs by High Content Screening 
Technique: Identification of Biocompatible Multifunctional Nanoparticles for 
Nanomedicine. Ieee Transactions on Magnetics, 2013. 49(1): p. 377-382. 
19. Chang Y, Lee GH, Kim TJ, Chae KS. Toxicity of Magnetic Resonance Imaging 
Agents: Small Molecule and Nanoparticle. Current Topics in Medicinal Chemistry, 
2013. 13(4): p. 434-445. 
 
124 
 
20. Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, et al. 
Superparamagnetic iron-oxide - pharmacokinetics and toxicity. American Journal 
of Roentgenology 1989,152:167-173. 
21. Jun Y-w, Huh Y-M, Choi J-s, Lee J-H, Song H-T, KimKim, et al. Nanoscale Size 
Effect of Magnetic Nanocrystals and Their Utilization for Cancer Diagnosis via 
Magnetic Resonance Imaging. Journal of the American Chemical Society 
2005,127:5732-5733. 
22. Koenig SH, Kellar KE. Theory of 1/t-1 and 1/t-2 nmrd profiles of solutions of 
magnetic nanoparticles. Magnetic Resonance in Medicine 1995,34:227-233. 
23. Wang YXJ, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast 
agents: physicochemical characteristics and applications in MR imaging. 
European Radiology 2001,11:2319-2331. 
24. Muller K, Skepper JN, Posfai M, Trivedi R, Howarth S, Corot C, et al. Effect of 
ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) on 
human monocyie-macrophages in vitro. Biomaterials 2007,28:1629-1642. 
25. Wuang SC, Neoh KG, Kang E-T, Pack DW, Leckband DE. HER-2-mediated 
endocytosis of magnetic nanospheres and the implications in cell targeting and 
particle magnetization. Biomaterials 2008,29:2270-2279. 
26. Mansoor A. Nanotechnology for Cancer Therapy. 1 ed: CRC Press; 2007. 
27. Sun SH, Zeng H, Robinson DB, Raoux S, Rice PM, Wang SX, et al. Monodisperse 
MFe2O4 (M = Fe, Co, Mn) nanoparticles. Journal of the American Chemical Society 
2004,126:273-279. 
28. Lee J-H, Huh Y-M, Jun Y-w, Seo J-w, Jang J-t, Song H-T, et al. Artificially 
engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nature 
Medicine 2007,13:95-99. 
29. Campbell JL, Arora J, Cowell SF, Garg A, Eu P, Bhargava SK, et al. Quasi-cubic 
magnetite/silica core-shell nanoparticles as enhanced mri contrast agents for 
cancer imaging. PLoS ONE 2011,6. 
  
125 
 
Chapter 4 
4.1.0 Targeted MR contrast materials 
The previous chapter focused on the fabrication and application of 
silica coated quasi cubic magnetic nanoparticles and their performance as 
an MR contrast agent. In this chapter we will investigate the application of 
such a material for the purpose of cell specific MR enhancement using 
further particle and surface modification.  
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4.1.1 Introduction 
The use of iron oxide based nanoprobes for targeted MR imaging 
has gained increasing attention, however very few of the materials 
demonstrated all the required attributes that the application requires. 
Colloidal stability, biocompatibility, small size distribution, low toxicity, 
high magnetisation values and simplistic fabrication of clinically relevant 
quantities; are all required of the material before it can be considered 
applicable in a broad sense. This chapter aims to present and discuss the 
fabrication of a magnetite based Herceptin modified nanoprobe based on 
the Mag@SiO2 material presented in the previous chapter.  
The Mag@SiO2 presented previously possessed many of the 
attributes required to satisfy the requirements for a magnetite based 
targeted MR nanoprobe, however it fell short on several aspects. The 
overall particle size needs to be reduced to ensure a long blood circulation 
time and the surface needs further modification to accommodate the 
attachment of a targeting antibody. Due to the difference to the previous 
material and addition of subsequent components, this chapter will denote 
the Mag@SiO2 particles as ―Fe@SiO‖ to avoid confusion and highlight the 
difference to the material previously produced.  
Imaging modalities can offer a way to monitor the response of 
patients to immune therapies and identify those that have stopped 
responding to the treatments. This is possible if an MR contrast agent is 
able to specifically target cancerous cells that overexpress certain surface 
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proteins such as HER2, the following chapter will discuss the role of 
magnetic nanoparticles for targeted imaging and the development of one 
such material based on the previously discussed Mag@SiO2. 
Currently, targeted imaging using iron oxide nanoparticles remains 
in the preclinical setting due the particles used being rapidly cleared from 
the body due to their large particle size. This was the first aspect of the 
previous Mag@SiO2 material that required improvement. Through finer 
control of the fabrication process and reduction of oleic acid 
concentration, smaller and more homogenous particles were able to be 
fabricated. Biocompatibility of these new particles had to be re-confirmed 
given the stark contrast in possible properties given size reduction. The 
silica surface coating process also needed greater control to produce a 
thinner surface that allowed further functionalisation. This was achieved 
by decreasing the rate of TEOS hydrolysis on particles pre functionalised 
with a layer of citric acid.  
The surface of the particles then had to allow for the strong 
adhesion of targeting molecules such as the antibody Herceptin®. This 
was accomplished by simple amine functionalisation to create a strong 
electrostatic bond. The toxicity of these magnetite-core\silica shell, 
Herceptin® coated particles (Fe@SiO@HER) was examined, as was the 
stability of the Herceptin® adhesion under physiological conditions. The 
methods and results of these modifications to the material will be 
discussed in the following sections along with the performance of this 
material as a targeted MRI contrast agent both in vitro and in vivo. 
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4.2.1 Materials and methods 
4.2.2 Reagents, chemicals and assay kits 
All chemicals were purchased from Sigma Aldrich Pty LTD and used 
as received without further modification. Cell lines (SKBR3, BT474 and 
MCF7) were purchased from American Type Culture Association (ATCC). 
CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega) kit 
was purchased from Promega Corporation. BCA protein assay was 
purchased from Invitrogen. Herceptin® was a generous gift from the 
Pharmacy Department at The Peter MacCallum Cancer Centre. 
 
4.2.3 Synthesis of magnetite particles 
The core magnetite particles were again synthesised using the high 
temperature thermal decomposition method previously used in chapter 3, 
modified from the work presented by Park et al. (2004) [1]. However 
different aging duration and capping agent quantities were used in order 
to produce a material with more desirable properties for the targeting 
application. 
An iron-oleate complex was first formed by dissolving 5.4 g of iron 
chloride and 18.25 g of sodium oleate in a solution comprised of 40 ml 
ethanol, 30 ml distilled water and 70 ml hexane. Once homogenised, the 
solution was refluxed at 70°C for 4 hours, followed by separation of the 
upper organic layer using a separatory funnel, washing and evaporating 
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off hexane, thereby leaving a waxy iron oleate complex. The iron oxide 
nanocrystals were formed by dissolving 9.0 g of the iron oleate complex in 
1.425 g of oleic acid and 63.3 mL of 1-octadecene, followed by reflux 
under nitrogen until it reached 320 °C, at which point the temperature 
was held for 20 minutes and the solution was then allowed to cool to room 
temperature.  
In order to gain greater control of the reaction an additional 
measure to ensure all water removal from the iron oleate complex was 
used. During the high temperature reflux step, the solution was first 
taken to 110 °C and all water vapour allowed to escape prior to continuing 
the temperature ramp to 320 °C. After cooling the solution to room 
temperature, 250 mL of ethanol was added to the solution and the 
magnetite particles were separated via centrifugation, followed by three 
wash cycles with ethanol. A yield of up to 9 g of magnetic nanoparticles 
per reaction was achieved under these laboratory conditions. 
 
4.2.4 Synthesis of Fe@SiO nanoparticles 
The as synthesised magnetite was then washed with 20 mmol nitric 
acid solution to remove any surface contamination prior to silica coating. 
The coating process was carried out much like it was before, using a 
modification of the Stöber method [2] described by Fang et al. [3], however 
a thinner layer of silica was to be deposited in this case.  
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2 mg of magnetite particles were first made hydrophilic by surface 
coating with citric acid. This was accomplished by refluxing the particles 
in 5 ml ethanol and 1 ml trisodium citrate solution (5 mg/ml) overnight. 
The resulting particles were washed from solution via centrifugation and 
washed 3 times in ethanol and MilliQ-water. 
These magnetite particles were then added to 15 ml of ethanol and 
3.75 ml Milli-Q water (4:1) and sonicated for 15 minutes. The water in the 
sonicator bath was maintained at 28°C to ensure a constant reaction rate. 
During the coating process the sonicator was switched on for 2 out of 
every 5 minutes. The magnetite particles were continuously stirred via an 
overhead stirrer fitted with a glass screw style stirring rod while the 1:160 
/ TEOS : ethanol solution was injected into the solution via a syringe 
pump at 0.1 ml/h.  
Immediately prior to beginning the TEOS injection, 0.5 ml ammonia 
(28%) was added to the ethanol, water and magnetite solution. This 
process was allowed to continue for up to 3 hours, the thickness of the 
silica shell could be altered by increasing or reducing the reaction time. 
The silica coated particles were then centrifuged out of solution and 
washed 3 times in ethanol and twice in water prior to redispersion in 
MilliQ-water. 
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4.2.5 Conjugation of Fe@SiO to Herceptin® 
The as prepared silica coated magnetite particles were surface 
treated with cysteamine to provide binding sites for the addition of the 
Herceptin® antibody. The silica coated particles were incubated in the 
presence of excess cysteamine (5 mg/ml) at room temperature on a rotary 
shaker for 2 hours (9 ml MilliQ-water, 1 ml cysteamine solution). The 
particles were then washed 3 times with MilliQ-water to remove excess 
cysteamine.  
2 ml Herceptin® solution (1 mg/ml) was added to cysteamine coated 
particles in 3 ml MilliQ-water and incubated with the cysteamine 
functionalised particles at room temperature on a rotary shaker for 2 
hours. The amount of Herceptin® conjugated on the surface of the silica 
coated magnetite was quantified using a BCA protein assay kit according 
to the manufacturer’s instructions.  
 
4.2.6 Assessment of Fe@SiO-HER stability 
4.2.6.1 Conjugation of FITC to Fe@SiO@HER 
In order to establish the stability of the silica-cysteamine-
Herceptin® linkage, firstly Herceptin® had to be conjugated with a FITC 
marker molecule, this was accomplished using a FluoroTag FITC 
conjugation kit (Sigma, USA). The Herceptin® was first purified using a 
Sephadex G-25M column (Pharmacia, Sweden) and then added to the 
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FITC using the small scale conjugation procedure following the 
manufacturer’s protocol. The FITC-Herceptin® complex was then 
conjugated to the surface of the Fe@SiO via the cysteamine linker after 2 
hours incubation time at room temperature. The FITC-Herceptin®-
cysteamine-silica particles were then washed 3 times in MilliQ-water via 
centrifugation. 
The now FITC conjugated Herceptin® functionalised (Fe@SiO@HER-
FITC) particles were dispersed in water and exposed to pH variances of 5, 
7.14, and 10 as well as human serum concentrations of 25%, 50% and 
100%. Release of the Herceptin® from the surface of the Fe@SiO was 
determined by the increase in fluorescence within the supernatant caused 
by loss of Herceptin® after 24 hours, compared to standards prepared 
using known concentrations of Herceptin®-FITC molecules. 
 
4.2.7 In vitro studies 
4.2.7.1 Cell culture 
Breast cancer cell lines, SKBR-3, BT474 and MCF-7 cells were 
routinely cultured at 37˚C in a humidified atmosphere with 5% CO2 using 
RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 1% 
penicillin, 1% streptomycin/penicillin and 1mM L-glutamine (Sigma 
Aldrich). For sub-culturing, cells were detached by washing with 
phosphate-buffered saline (PBS) and incubating with trypsin-EDTA 
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solution (0.25% trypsin, 1 mM EDTA) for 4 mins at 37 ˚C, followed by 
washing and incubation with supplemented RPMI 1641 medium.  
 
4.2.7.2 Cytotoxicity studies 
To assess cytotoxicity of the iron oxide-silica Herceptin® 
nanoparticles on breast cancer cells, the viability of SKBR-3 cells 
incubated with the Herceptin® labeled particles was assessed after 24 and 
48 hours in vitro. SKBR-3 cells were seeded into 24-well plates for 24 
hours, after which medium without serum was added with iron oxide-
silica nanoparticles at concentrations ranging between 1 to 100 µg/ml. A 
CellTiter 96 AQueous One Solution Cell Proliferation Assay kit (Promega, 
USA) containing the tetrazolium compound 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) was 
used to monitor cell viability according to the manufacturer’s instructions 
and the MTS colour change was measured at 490 nm using a microplate 
reader and cell viability was plotted against 100% viability for untreated 
cells. 
 
4.2.8 Cellular uptake 
4.2.8.1 Confocal microscopy 
SKBR3, BT474 and MCF-7 cell lines were cultured and seeded onto 
a 6-well slide glass chamber. All cell lines were incubated with 1 ml of 50 
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µg/ml Fe@SiO@HER-FITC nanoparticles for 4 hours at 37oC and cellular 
uptake was assessed by confocal microscopy. Thirty minutes prior to 
imaging, a Hoechst nuclear stain was added to the cells and then washed 
several times with PBS to aid in the identification of live cells within the 
culture.  
 
4.2.8.2 Flow cytometry 
To quantify the uptake of the iron oxide-silica Herceptin® 
nanoparticles by SKBR3, BT474 and MCF7 cells, dose response and time 
course studies were performed using flow cytometry. Cells were grown to 
90% confluence in 24-well plates and for the dose-response study; 10 
µg/ml, 50 µg/ml and 100 µg/ml of iron oxide-silica Herceptin® 
nanoparticles were added to cells and incubated for 24 hours. For time-
course studies, Fe@SiO@HER nanoparticles conjugated to FITC were 
incubated at varying time points of 0.5, 1, 3, 5 and 24 hours, at a 
constant concentration of 50 µg/ml. After incubation for both dose-
response and time-course studies, the cells were detached from the plates 
with trypsin-EDTA and washed twice in PBS and resuspended in FACS-fix 
buffer for analysis by flow cytometry and a minimum of 8,000-10,000 
viable cells were assayed (FACSCanto, BD Biosciences, RMIT Flow 
Cytometry Facility, Bundoora, Australia).  
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4.2.9 Quantification of HER-2 expression 
Quantification of HER-2 expression levels between SKBR-3, BT474 
and MCF-7 cells was assessed by flow cytometry. Cells were cultured 
using the previously mentioned method, seeded onto 24-well plates and 
grown to 90% confluency. Herceptin® was added to the cells at a 
concentration of 10 µg/ml for 30 min at 4oC followed by two washes and 
then incubation with FITC-anti-human IgG secondary antibody for 30 min 
at 4oC. The removal of the primary antibody from these treatments was 
used as a measurement of non-specific binding of the secondary antibody. 
The cells were washed and then analysed by flow cytometer as previously 
described. The mean fluorescence intensity (MFI %) was determined by 
subtracting the mean channel number for the background from the mean 
channel number for the primary antibody treated cells. 
 
4.2.10 MR imaging 
4.2.10.1 MR Imaging in vitro 
Iron oxide nanoparticles were prepared and conjugated to 
Herceptin® using the described protocols. SKBR-3, BT474 and MCF-7 
cells were cultured, detached using trypsin-EDTA solution, washed and 
seeded onto 6-well plates and incubated with supplemented RPMI 1641 
medium without serum. Each cell line was treated with 1 ml of 50 µg/ml 
of Fe@SiO@HER and incubated for 5 hours at 37˚C. Before imaging on 
MRI, the cells were washed 3 times with PBS and then fixed with 
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glutaraldehyde. A T2-weighted gradient echo sequence was used with the 
same parameters as the phantom studies. Signal enhacement of each of 
the cell lines was calculated relative to the control using:  
∆R2/R2control  100. 
 
4.2.10.2 Mouse Experiments 
We obtained ~6 week old female BALB/c nude mice (ARC) in 
accordance with the guidelines and under approval of the Animal Ethics 
Committee of RMIT University (RMIT AEEC approval number: 0906). The 
nude mice were injected subcutaneously with equal volume of SKBR3 
cells (2.5 x 106) and Matrigel (BD, USA) into the right flank. A full tumour 
growth analysis was conducted to ensure growth of the tumours as well as 
the average time to reach a maximum diameter of approximately 1 cm. 
4.2.10.3 MR imaging in vivo 
Nude mice (n = 15) bearing SBKR3 tumours were studied by MRI 
when the subcutaneous tumours reached a diameter of approximately 1 
cm. A solution of Fe@SiO@HER particles (400 µg Fe) was infused via the 
tail vein of a group of mice and a solution of Fe@SiO particles (400 µg) was 
infused via the tail vein of another group of mice. The MRI of ketamine-
xyalazine-anesthetised mice was performed at 4 and 24 hours using a 3.0 
T magnetic resonance scanner and a heel coil. All animals were measured 
using a T2-weighted sequence. 
137 
 
 
4.3.1 Results and discussion 
The previous study demonstrated many of the advantages of using a 
material such as this for MR contrast enhancement, however the particles 
investigated in chapter 3 had several physical characteristics that could 
be improved upon for use in targeted MR contrast enhancement. Firstly 
the size and morphology of the material required greater control; this was 
achieved through modifying the amount of oleic acid present in last phase 
of the fabrication. This change was based on work by Song et al. [4] 
whereby the size and shape of the particles produced by the high 
temperature decomposition method was modified by altering the amount 
of oleic acid present in the reaction. By reducing the amount of oleic acid 
and decreasing the aging duration of the process, spherical magnetite 
particles with an average diameter of 17 nm could be obtained. The 
thickness of the silica coating on the particles was also decreased in order 
to form a core shell system with an overall diameter of less than 60 nm.  
This was required to increase the blood half-life of the particles so 
that they could localise at the target site without being removed by the 
RES prior to imaging. Previously in chapter 3 we presented in vivo imaging 
data produced by directly injecting the particles to the target site. However 
in this chapter we will be delivering the particles via intravenous injection 
and allowing the particles to self-direct to the tumour site with the aid of 
targeting antibodies.  
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Given the fundamental changes made to the contrast material, all 
relevant characterisations had to be made using the new material. The 
following sections discuss the results obtained while examining the 
particle size, solubility, biocompatibility, targeting ability and image 
contrast capabilities, of the newly synthesised particles.  
 
4.3.2 TEM analysis 
Figure 1 shows the TEM images of both the as synthesised and 
silica coated iron oxide nanoparticles. The micrograph of the as 
synthesised particles (Figure 1(A)) shows that they have a mean particle 
diameter of 17 nm and are both spherical and have a homogenous size 
distribution. Figure 1 (B) shows the particles after silica coating in which a 
silica shell of ~10 nm has been coated onto the surface of the particles to 
infer stability in water, biocompatibility and provide anchorage sites for 
the addition of the Herceptin® antibody. The image shows that the silica 
coating has formed in a smooth continuous layer around the outside of 
the magnetite particle, the majority of the particles contain only a single 
core and very little aggregation has occurred during the coating process.  
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Figure 1: TEM image of as synthesized magnetite and Fe@SiO particles, Scale bar is 
equal to 50 nm. 
 
 
Figure 2: Histogram outlining the particle size distribution of the as synthesized 
magnetite particles. 
For successful MRI applications in vivo, the iron oxide nanoparticles 
need to have an overall size smaller than 60 nm in diameter [5]. This 
consideration arises because studies have reported that particles larger 
than this size limit cell targeting capability and reduce uptake efficiency 
[5]. Another problem that occurs due to larger particle size is non-specific 
uptake in the RES as well as biological instability [6]. In our previous 
investigation we reported iron oxide silica nanoparticles with a diameter of 
greater than 60 nm, making these particles unsuitable for in vivo targeted 
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MRI. Therefore the method of synthesis was modified to reduce the size of 
the particles making them suitable to in vivo. The TEM images illustrates 
that the total particle diameter after silica coating is approx. 50 nm, which 
should reduce the RES uptake and should infer a longer blood circulation 
time and greater uptake at the target site. 
 
4.3.3 XRD analysis 
The XRD analysis in Figure 3 shows little difference to the quasi 
cubic particles discussed in the previous chapter. The main feature that 
sets them apart is the broadening of the peaks in this sample. This is due 
to the smaller overall particle size of this material; however all of the 
characteristic peaks remain, albeit to slightly different ratios. The sample 
presented an acceptable match with the same magnetite card file as before 
(75-0449) however in this case the dominance of the (311) peak is not 
absolute. The (440) peak has increased in intensity significantly which 
may be due to either the size of the particle being restricted or a more 
controlled thermal deposition process. Again we expect there to be 
hematite and maghemite present in the material and it is not possible for 
XRD to adequately distinguish between the two oxidation states, however 
given the colour and magnetic performance of the particles, we determine 
that the majority of the material present in the sample remains as 
magnetite.  
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Figure 3: XRD pattern for the as synthesised 17 nm magnetite particles. 
 
4.3.4 Herceptin® conjugation 
Herceptin® was then conjugated to the surface of the silica coated 
magnetite particles using cysteamine as a crosslinker. The cysteamine 
molecule binds to the surface of the silica via attachment to the silanol 
groups present on the surface, this leaves free amine groups on the 
surface being presented from the tail end of the cysteamine molecule. 
These amine groups provide an anchorage site for the carboxylic groups 
present on the tail end of the FC region of the Herceptin® antibody. 
The chemistry of the nanoparticles-cysteamine-Herceptin® 
conjugation indicates the particles are bound electrostatically. The 
formation of the Fe@SiO@HER nanoparticles was confirmed and 
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quantitated by a bicinchoninic acid (BCA) protein assay kit. After 
conjugation, the particles were washed of any free unbound Herceptin® 
and the remaining material had its protein concentration quantified. This 
demonstrated that the Herceptin® had both bound to the surface of the 
silica and that it did so at a concentration of 0.66 µg of Herceptin® per 1 
µg of iron oxide silica particles.  
For in vitro and in vivo studies, stability of the Herceptin® 
conjugation within the application environment is critically important. In 
order to determine that the Herceptin® was sufficiently bound to the 
surface, the iron oxide silica Herceptin® nanoparticles were incubated 
over a 24 hour period across a range of pH and human serum 
concentrations. The Herceptin® was first conjugated with FITC markers 
and then attached to the silica surface. The particles were then incubated 
under the varying conditions for 24 hours and centrifuged at 4000 rpm to 
pellet out the particles and the Herceptin® that remained bound. The 
supernatant was analysed and the proportion of free Herceptin® was 
calculated using a standard curve produced by a known concentration of 
FITC-Herceptin® conjugates.  
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Figure 4: % of Herceptin® lost from the particles after incubation for up to 24 h in 
varying pH ranging from 5-10 
 
Figure 5: % Herceptin® lost from particles after incubation for up to 24 h in human 
serum concentrations ranging from 25-100% 
 
The results in Figures 4 and 5 show that across this range of pH 
and human serum, the Herceptin® conjugation holds up exceptionally 
well with only up to 3.7 % being lost from the surface. It can therefore be 
concluded that under these conditions very little Herceptin® is lost due to 
the effective linkage via the cysteamine. These stability results are similar 
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to other studies that have reported stable particle conjugations in various 
pHs indicating that competitive displacement in vivo is unlikely [7]. 
 
4.4.1 In vitro and in vivo studies 
The in vivo and in vitro studies presented demonstrate that the 
Fe@SiO@HER particles were capable of producing localised MR contrast at 
the site of cells expressing a specific surface marker. The particles were 
also capable of localising at the target site after intravenous 
administration in suitable concentration to provide substantial contrast 
enhancement. This data suggests that the Herceptin® functionalised 
particles were able to specifically target cells that over expressed the 
HER2 surface receptor present in many breast tumours. 
 
4.4.2 Cytotoxicity 
It is well known that iron oxide particles can produce cell toxicity in 
high concentrations [8-10] and that silica coating has previously 
demonstrated to provide an increase in biocompatibility as well as particle 
stability [11, 12]. It is also plainly understandable that Herceptin® is 
cytotoxic to tumour cells as it undergoes internalisation via receptor-
mediated endocytosis at the HER2 receptor site and then causes down 
regulation of HER2 production eventually causing cell death. [13-14]  
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To investigate the cytotoxic potential of the iron oxide silica 
Herceptin® nanoparticles, MTS based assays were conducted on SKBR3 
cells (Figure 6). SKBR-3 cells were incubated with iron oxide silica 
Herceptin® nanoparticles for 24 and 48 hours at varying concentrations 
ranging from 1-100 µg/ml. Figure 6 shows that lower concentrations (1-30 
µg/ml) have no significant toxicity on SKBR-3 cells however the toxic 
effect increases between 50-100 µg/ml. 
 
 
Figure 6: % viability of SKBR3 cells after incubation with increasing concentrations of 
Fe@SiO@HER particles over a 24 and 48 hour period. 
 
These results are consistent with the low concentration of 
Herceptin® which is far lower than the therapeutic dosage when used as 
an independent treatment, having little toxic effect on the cells. The cell 
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death trends that are observable are quite similar to the previous study 
examining the cell toxicity of Mag@SiO2 particles in chapter 3 undergoing 
non-specific uptake. This means that in this case, the Herceptin® is 
behaving purely as a targeting moiety and is causing no additional 
cytotoxicity. Similar results have been reported for larger iron oxide 
particles that have been conjugated with Herceptin® and compared their 
cytotoxicity to SKBR3 cells. [15-19]  
 
4.4.3 Uptake specificity 
We then examined the in vitro binding specificity and efficiency by 
dose response and time course of Fe@SiO@HER nanoparticles by breast 
cancer cell lines that express different amounts of HER2 and analysed by 
flow cytometry. Initially, expression of HER2 was assessed in SKBR3, 
BT474 and MCF-7 cell lines. Analysis by flow cytometry showed that 
SKBR3 showed the highest HER2 expression followed by BT474 and then 
MCF-7 (Figure 7). 
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Figure 7: Relative surface expression of HER2 receptor between SKBR3, BT474 and 
MCF7 as measured by flow cytometry. 
 
The results of this study are consistent with the literature which 
indicates that amongst SKBR3, BT474 and MCF-7, SKBR3 cells have the 
highest HER2 expression [20, 21]. Although the expression levels of these 
cell lines are well known and widely reported, it was important to confirm 
expression levels as factors such as passage number, freezing, thawing 
and cell culture techniques can decrease expression levels within 
individual samples. The results are shown in Figure 7 where it can be 
clearly seen that SKBR-3 cells significantly overexpress the HER2 surface 
protein in comparison to the BT474 and MCF7 cell lines. 
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4.4.4 Cell specific uptake 
In order to achieve targeted imaging, the Fe@SiO@HER particle 
must be able to specifically bind to target cells. In this case Herceptin® is 
being used to target cells that overexpress the surface protein HER2, 
however as the HER2 protein is expressed in many cell types to a far 
lesser extent; quantification of particle uptake vs. surface expression must 
be compared. To first demonstrate that highly expressing SKBR-3 cells 
would internalise the particles, FITC-labeled Fe@SiO@HER nanoparticles 
were analysed by confocal microscopy. SKBR-3 cells were incubated with 
50 µg of FITC-labeled Fe@SiO@HER nanoparticles for 3 hours at 37oC, 
after this time the cells demonstrated significant uptake (Figure 8).  
 
 
Figure 8: Confocal microscopy images of SKBR3 cells after incubation with FITC- labelled 
Fe@SiO@HER for 3 hours. Scale bar 30 µm. 
 
The images in this study are similar to that of previous studies that have 
looked at the uptake of Herceptin® conjugated nanoparticles by SKBR-3 
cells [15, 22]. It is well known that HER2 is involved in receptor mediated 
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endocytosis, therefore resulting in the Herceptin®-tagged nanoparticles 
being accumulated within the cells. 
The mechanism of cellular uptake by the Fe@SiO@HER 
nanoparticles should be mediated by, and dependant on, Herceptin®. 
Therefore cells that express higher numbers of HER2 surface proteins 
should internalise more particles. To confirm this, a dose response and 
time course response of Fe@SiO@HER nanoparticles by SKRBR3, BT474 
and MCF7 was conducted. For the dose response study, the 
Fe@SiO@HER-FITC nanoparticles were incubated at different 
concentrations (5, 10, 50, 100 µg/ml) for 24 hours with the SKBR3, 
BT474 and MCF7 and then analysed by flow cytometry.  
 
 
Figure 9: Dose response data for SKBR3, BT474 and MCF7 particle uptake proportional 
to increasing particle concentration after 4 hours. 
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The results indicate that level of FITC fluorescence increases as the 
concentration of the Fe@SiO@HER nanoparticles increases in all cell lines 
suggesting, that more nanoparticles are being internalised with increasing 
exposure duration (Figure 10). Furthermore, the level of iron oxide silica 
Herceptin® FITC nanoparticle uptake is consistent with the amount of 
HER2 expression shown in Figure 7 for each of the cells lines, indicating 
specific HER2 mediated uptake.  
The results from this study are in accordance with cellular uptake 
studies of human serum albumin nanoparticles conjugated to Herceptin® 
which also demonstrate increasing uptake of nanoparticles as 
concentrations climb [23, 24]. It is interesting to note that most of the 
studies that use nanoparticles conjugated to Herceptin® do not show dose 
response uptake studies and instead only show the differences in uptake 
via MRI.  
For example the study by Chen et al [15] investigated the use of 
Herceptin® conjugated dextran-coated iron oxide nanoparticles in vitro 
and vivo in 4 human breast cancer cells lines. This method is essential in 
understanding the MRI contrast enhancement behaviour between 
phantoms and in vitro systems. However this is not useful in 
understanding the behaviour of the tagged nanoparticles in in vitro 
biological systems.  
In addition to dose response, the time required for uptake of 
nanoparticles is of critical importance when considering further clinical 
applications of such a material. Time-dependent cellular uptake of 
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Fe@SiO@HER nanoparticles were carried out using a constant 
concentration of 50 µg Fe and were incubated with SKBR3, BT474 and 
MCF7 for 30 mins, 1 hr, 3 hr, 5 hr and 24 hr (Figure 10). Similarly, the 
results show that as the time increases, nanoparticle uptake also 
increases and the rate of uptake appears to be consistent with the surface 
expression of the cell lines as shown in Figure 7. These findings are 
concurrent with previous studies suggesting uptake to be associated with 
HER2 receptors [21, 25].  
As with the dose response studies, there is limited data available on 
time course response studies of nanoparticles conjugated to Herceptin® 
except for one study showing uptake of HSA conjugated to Herceptin® in 
SBKR3, BT474 and MCF-7 cells over a 24 hour time period [21]. The 
results showed time dependant uptake of the nanoparticles and the 
influence of incubation times greater than 5 hours to be associated with 
non-specific uptake.  
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Figure 10: Particle adsorption time course for SKBR3, BT474 and MCF7 cells up to 24h 
incubation. 
 
4.4.5 Phantom cell studies 
The ability to provide contrast in phantoms and then in vitro using 
MRI is one fundamental aspect in targeted imaging. Another important 
aspect is the ability for the targeted nanoparticles to demonstrate selective 
binding at the target cells. In this case, the Fe@SiO@HER particles show 
selective binding as indicated by the dose and time course response 
studies, (Figure 9 and Figure 10). This selective binding is also effective 
enough to accumulate enough particles at the target site to generate 
significant contrast in a clinical MR scanner. This can be visualised in 
Figure 11 where SKBR3 cells appear darker relative to BT474 and MCF-7 
cell lines which is also confirmed by a plot of the drop in T2 values against 
the cell lines (Figure 11). The signal enhancement relative to the control of 
SKBR-3, BT474 and MCF-7 cells were calculated to be 52.3%, 34.7% and 
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12.5% respectively, compared to their control. With a maximum T2 value 
of 252.7 L/mmol/s in cell free suspensions, this value is only slightly less 
than that produced by the larger quasi cubic particles presented in 
chapter 3 which had a maximum value of 263.23 L/mmol/s. 
 
 
Figure 11: Bar graph and corresponding MR images showing contrast for each cell line 
after incubation with 50 µg/ml Fe@SiO@HER particles. 
 
These results are consistent with the surface expression data from 
Figure 7 suggesting that as the uptake of Fe@SiO@HER particles is 
proportional to the surface expression of HER2 within the cell line. This is 
confirmed by the higher T2 contrast observed in SKBR-3 cells compared 
to either the BT474 or MCF-7 when washed after incubation with equal 
amounts of Herceptin® conjugated iron oxide particles. 
On the basis of our successful verification that selective targeting 
can be achieved in vitro, we wanted to further examine their performance 
in an in vivo environment. For this study SKBR-3 tumours were to be 
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grown in BALB/c nude mice up to a diameter of 8mm2 over 12 days. The 
tumours were to be dissected and immunohistochemical analyses run to 
ensure expression of HER2 within the tumours grown in vivo. The tumour 
carrying mice were then be intravenously injected with Fe@SiO@HER 
particles and then MR images taken of the tumour sites to determine if 
significant uptake occurred. This experiment was approved by the RMIT 
AEEC, approval number 0906 and all animal treatment procedures were 
adhered to stringently. 
 
4.4.6 In vivo mouse imaging 
 Nude mice (n=15) were subcutaneously injected with SKBR3 cell 
lines which overexpress HER2 receptors and the tumours were allowed to 
grow to 8mm2 prior to beginning the experiment. In order to ensure that 
the SKBR-3 tumours grown in vivo expressed HER2 surface proteins, 
immunohistochemical analysis of SKBR3 xenograft tumours was 
performed. Following the growth of xenograft SKBR3 tumours in BALB/c 
nude mice, the mice were sacrificed; their tumours were dissected and 
processed for histological analysis. Figure 12 shows the staining pattern 
of HER2 in SKBR3 xenograft tumours grown in BALB/c nude mice. The 
inset shows clear membranous (M) and cytoplasmic (C) staining when 
stained with an anti-HER2 antibody. This pattern of staining was 
consistent with tumours that are expressing the HER2 surface protein. 
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Figure 12: Histological analysis of BALB/c nude mouse tumour, stained with anti-HER2 
antibody, scale bar 1000 µm. 
 
MR imaging of the mice was performed at 4 hours after intravenous 
tail injection. The study consisted of two control groups (saline and 
Fe@SiO) and one experimental group, Fe@SiO@HER. The first set of 
control subjects received only saline and the second set received 400 µg of 
Fe@SiO nanoparticles with no Herceptin® bound to its surface. The 
experimental group received 400 µg Fe@SiO@HER nanoparticles. Figure 
13 shows the MR images at 4 hours post injection of the three groups. The 
results indicate that by 4 hours post injection, uptake of the 
Fe@SiO@HER particles can be seen as indicated by the contrast 
enhancement relative to the control. 
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Figure 13: MRI comparison of SKBR3 tumours in mice 4 hours post injection, tumour 
regions highlighted. 
 
 
Figure 14: Signal enhancement values calculated via MR readout for the tumour sites 
between the three variables. 
 
To further confirm the specific binding, the signal enhancement was 
also calculated against the second control group which received Fe@SiO 
nanoparticles (Figure 14). By directly comparing these results we can 
confirm that it is the addition of the Herceptin® targeting moiety to the 
surface of the particles that allows the material to be specifically targeted 
towards HER2 expressing cells. We can also conclude that not only do the 
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particles specifically target cells that over-express the HER2 protein; but 
that they do so in such number that significant contrast can be added to 
an MR image by the intravenous injection of the particles under clinical 
conditions. 
 
4.5.1 Conclusions 
We have been able to demonstrate the applicability of silica coated 
magnetite particles using a targeting moiety, for cell specific contrast 
enhancement. Under clinical conditions using clinical scanning protocols, 
we were able to produce significant contrast at a target site in breast 
tumour bearing mice 4 hours post injection. This clearly demonstrates 
that the particle circulation time is great enough to overcome the RES 
uptake and excretion issues that have rendered other nanomaterials 
ineffective for this application. The Fe@SiO@HER material has 
demonstrated low cytotoxicity at clinical dosages, the ability to produce 
significant contrast and good functional stability under a range of pH and 
serum concentrations. The particles themselves can be made in large 
enough amounts that they can be considered for human clinical 
application and the method of production provides good size and shape 
homogeneity.  
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Chapter 5 
5.1.0 Further investigations 
 
The previous chapters outlined the development and application of a 
silica coated magnetite particle for MR contrast applications. This included 
the modification and attachment of Herceptin® biomarkers to allow for 
specific targeting on the cellular level of this material. This chapter aims to 
investigate some of the further applications this material may yield. A Brief 
introduction to induction heating will be presented prior to experimental 
and discussion information. However, as much of the reasoning and 
pertinent literature has been discussed in chapter 1, only a very brief 
overview of DMSA coatings will be covered prior to its discussion. These brief 
investigations serve only to highlight the additional application possibilities 
based on the materials previously presented and not in themselves full 
studies. Although some data is presented and discussed, it is outside the 
purview of this thesis to completely investigate these applications. 
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5.1.1 Radio frequency induced heating 
5.1.2 Introduction 
Among their interesting properties, magnetic nanoparticles also 
possess the ability to be used as nanoscopic heating elements. This is due to 
their ability to release excess adsorbed RF energy as heat, as their magnetic 
field is forced to alternate direction. This is due to the particle having some 
magnetic hysteresis that does not spontaneously realign with the applied 
field. This delay in alignment causes energy loss in the form of heat, which 
is transferred to the environment. This principle has been well understood 
for many years and magnetic induction heaters are used in industry and 
even in modern kitchens as stovetops. However, the ability for a nanoscopic 
probe to emit heat has possible applications in medicine; specifically in 
experimental cancer treatments [1-5]. 
Hyperthermia (raising temperature), treatments have been used in the 
fight against cancer for some time and established methods have yielded 
several approaches using localised heating to weaken or kill cancerous cells. 
Given the delicate mechanisms that run the cells in our bodies, little rise in 
temperature is required to upset a cells functioning, ~42+ °C [6-8]. 
Commonly the methods of heating the affected area are via infra-red, 
ultrasound, RF ablation or blood perfusion. Although these methods can be 
targeted at specific areas, they are still unable to distinguish healthy from 
cancerous tissue, while perfusion is completely systemic. However the 
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properties of targeted nanoprobes capable of cell specific localisation, offer 
new opportunities and enhanced performance to these treatments. 
Effective hyperthermia treatments are tantalising partly because they 
are a physical treatment and as such there is less build-up of toxins like 
during chemotherapy. This reduces possible side effect and allows for more 
rigorous and repetitive treatments with less ill effects on the patients healthy 
tissues. Often hyperthermia treatments are used in conjunction with 
conventional treatments. This is due to the hyperthermia treatment making 
the cancerous cells more vulnerable to treatments such as chemo and 
radiotherapy [2-5, 9].  
Though promising, these treatments are still limited by the current 
technological state of the heating materials. Targeted nanoprobes capable of 
emitting sufficient heat at a target site would make these treatments far 
more effective. Furthermore, these materials could be combined with 
thermoresponsive polymers to allow the targeted and RF induced release of 
drug molecules. This second approach would make best use of the 
synergism between the two treatment styles, temperature and chemical; and 
may offer a new range of treatment practices for cancerous tissue. 
To this end, we investigated the potential RF induced heating 
properties of the Fe@SiO particles fabricated and discussed in chapter 4. It 
is currently understood that particles that produce the best specific loss 
power (SLP) ratios are those that fall between the dimensions over which the 
material is transitioning between its superparamagnetic and stable 
ferromagnetic states [1]. Given the approximate range of this transition for 
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our materials being 20 nm, it was likely that our material did possess these 
properties [1].  
 
5.1.3 Experimental and Discussion 
This work was overseen and carried out in the hyperthermia materials 
labs at Southeast University in Nanjing PR China under the guidance of 
Professor Gu Ning and Dr. Ma Ming during the course of an ENDEAVOUR 
fellowship. Heating rate experiments were undertaken using an induction 
heating oven (Figure 2) at 13 amps and 400 kHz. Temperature was read 
every 30 seconds using a precision alcohol thermometer. Samples 
containing approximately 2 mg of Fe were coated in 5 nm of SiO2 using the 
methods described earlier in section 4.2.4. The particles were dispersed via 
sonication in 5 ml MilliQ-water to yield a particle solution of approximately 
10 µM Fe. Two different materials had their resultant heating rates 
compared; these were magnetite produced via aqueous co-precipitation (AC 
Mag) and thermal decomposition (TD Mag).  
The particles were characterised via TEM, images are shown below in 
Figure 1. The comparative particle shape polydispersity can be observed 
between the two production methods. Thermal decomposition (Figure 1 A) 
produces smaller, more homogenous spherical particles which have been 
presented previously in chapter 4. Aqueous co-precipitation on the other 
hand, produces larger triangular and cubic nanoparticles of a more 
polydisperse nature (Figure 1 C). The TEM images show that a uniform 
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coating of SiO2 deposited on the surface of the particles however some 
aggregation has occurred possibly due to the coating process.  
This aggregation may alter the performance of the particles as heating 
elements due to the interaction of individual dipoles affecting the hysteresis 
properties of the particles. This may be a source of concern and interest in 
further studies, however in this case we are only seeking to reveal the basic 
heating properties of TD Mag before and after a silica coating has been 
applied. Given that similar aggregation has occurred in both samples we feel 
that for the purposes of this basic study, the materials remain comparable 
for basic properties.  
 
 
 
 
Figure 1: TEM images of the prepared particles. A) as prepared TD Mag, B) TD Mag 
with 5 nm SiO2 coating, C) as prepared AQ Mag, D) AQ Mag with 5 nm SiO coating. Scale 
bar 50 nm. 
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Figure 2: Induction furnace used for heating experiments at Southeast University Nanjing, 
China. 
 
The materials produced via aqueous co-precipitation were known to 
perform well at induction heating yet poorly as MR contrast due to their low 
magnetisation values. This material was prepared and included as a positive 
control and performance comparison for the materials produced via thermal 
decomposition. The graph below demonstrates the increase in temperature 
over time for the materials tested. 
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Figure 3: Heating rate comparison between the magnetite produced through aqueous co 
precipitation (AC Mag) and thermal decomposition (TD Mag) before and after a 5 nm layer of 
SiO2 is added. The dotted line shows the time taken to reach the clinically useful 44°C 
mark. 
 
As expected the materials produced by thermal decomposition 
increased the temperature of the water more slowly, however they were able 
to reach 44 °C after 6-8 minutes. From this preliminary data we can see that 
the Fe@SiO particles produced as a base for targeted MR contrast in the 
previous chapter (TD Mag) also possess the ability to act as nanoprobes 
capable of RF induced heating. Both materials show a decrease in heating 
rates with an added SiO2 layer which is to be expected. However the time 
taken to reach 44°C remains below 10 min and would still be easily 
accommodated in a clinical timeframe. 
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5.1.4 Conclusion 
We have previously shown that the Fe@SiO particles can be 
conjugated with biomarkers which allow them to specifically target certain 
cell lines for uptake (Chapter 4). We have now demonstrated that these 
same materials can be used to some extent for RF induced heating 
applications. The data presented merely indicate that the materials have 
heating capabilities and further testing would be required in order to 
determine if these properties are at all significant in a clinical sense. 
However these materials may display enough heating capability to be used 
in conjunction with thermally induced drug release systems. To these ends 
we believe that these materials deserve further investigation along these 
lines and may provide an interesting platform for future targeted MR 
contrast/hyperthermia/drug delivery systems. 
 
5.2.1 DMSA coatings 
As discussed previously in chapter 1 section 1.8.3, DMSA is a well-
known biocompatible surface coating. It offers many properties that may 
make it desirable for medical applications, such as available carboxylic and 
thiol groups for further functionalization. However the layer created is not 
thick enough to fully separate the magnetic dipoles of the particles to the 
same extent as the silica coating that was used throughout chapters 3 and 
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4. Also, as there are both thiol and carboxylic groups on the surface, this 
may cause additional complication for further functionalisation.  
However DMSA is exceptionally biocompatible and behaves as an 
excellent particle stabiliser with a relatively easy coating process. To these 
ends, the materials produced in chapter 3, the quasi cubic ―Mag‖ particles, 
were examined for their comparative performance in some circumstances 
similar to those of the Mag@SiO2 particles. The depth of the study was 
however, not to the same extent as previously discussed. This was partly 
because the MRI scanners we were using for the research were clinically 
active machines; this meant that we could not allocate time on the 
instrument for less promising materials. However we were interested in the 
properties of DMSA as a biocompatible surface coating and how it affected 
the magnetic properties of the particles in contrast to the silica.  
The particles were examined for their biocompatibility, magnetisation 
saturation and subsequent phantom MR performance. These experiments 
were done in conjunction with those discussed in chapter 3 and follow the 
same methodologies. Given the short nature of this chapter please refer to 
chapter 3 for specific experimental imaging information. 
  
5.2.2 Surface coating 
5 mg of Mag particles were dispersed in 10 ml dry toluene and 2.5 mg 
(14 µmol) DMSA (Sigma). The solution was sonicated for 20 minutes and 
then placed on a rotary shaker at room temperature for 24 hours. The 
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particles were centrifuged out of solution and washed 3 times in ether and 3 
times in MilliQ-water. The particles were re dispersed in 5 ml MilliQ-water 
and adjusted to 100 µg/ml using AAS for loss quantification. 
 
5.2.3 Experimental and discussion 
Figure 4 shows the morphology of the Mag particles after coating with 
DMSA. Given the low electron density of the organic DMSA layer, it is not 
expected that there be much of a visible layer on the surface under TEM 
examination. However given the close stacking of the particles to each other 
after DMSA coating, it can be deduced that the surface coating remains 
relatively thin. The particles also do not seem to be engulfed in an 
amorphous glob of DMSA but this was unlikely given the exceptionally low 
quantity of DMSA used in the coating process. 
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Figure 4: TEM image of the DMSA coated Mag particles, scale bar 50 nm. 
 
Identically to the process used in section 3.3.1, biocompatibility of the 
DMSA coated particles was ascertained via MTS assay. Viability was 
assessed across an increasing concentration range and at both 24 and 48 
hours. The particles show very little toxicity in Figure 5 at low to mid-range 
concentrations, the only significant decline occurs at the maximum 100 
µg/ml concentration. However there is significantly larger error variance in 
the data for these samples compared to those of the Mag@SiO2 particles 
discussed in chapter 3. This may be due to DMSA inducing cell proliferation 
or simply decreasing uptake, however DMSA has been readily used in 
cellular uptake studies by other groups [10-12]. This data demonstrates the 
high level of biocompatibility that DMSA has been known to exhibit and 
should serve to encourage its use when such properties are required. 
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Figure 5: Biocompatibility of DMSA coated magnetite particles at increasing concentrations 
over 24 and 48 hours. 
 
The SQUID data presented in Figure 6 demonstrates the lessening of 
the magnetisation saturation of the material while its individual dipoles are 
allowed into closer proximity than the same material used in chapter 3. This 
lessening of the emu/g value was expected and is reinforced by the 
lessening of the obtained signal intensity and subsequent contrast reduction 
(Figure 7).  
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Figure 6: SQUID data showing magnetisation saturation of DMSA coated Mag particles. 
 
The phantom study echoed the results from the SQUID analysis, lower 
emu/g values translated into less T2 contrast versus the water control. 
Below in Figure 7 the relative contrast is shown for the DMSA coated Mag 
particles at an increasing concentration compared to the control at 0 µg Fe. 
Given the results discussed in section 3.4.5 regarding the decrease in 
contrast signal after cellular uptake for the Mag@SiO2 particles, we would 
expect similar behaviour from the DMSA coated material. 
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Figure 7: Relative signal enhancement of DMSA coated magnetite particles compared to 
control under phantom imaging parameters. 
 
5.2.4 Conclusion 
The cell viability study demonstrated the excellent biocompatibility of 
DMSA as is widely known and used in literature [10-12]. However, likely due 
to the exceptionally thin coating produced by the DMSA, there is a greater 
dipole interaction between the particles which allows for a lowering of the 
magnetic susceptibility. This is observable in the TEM and SQUID data 
(Figures 4 & 6) which results in less overall contrast in the phantom images, 
(Figure 7). 
 
Given the results from these brief experiments, DMSA may provide an 
interesting avenue for particle stabilisation and biocompatibility 
improvements for these materials. Far deeper study would be needed to 
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properly ascertain its potential, but it may offer good properties for 
applications in cell tracking where specific targeting is not required. It would 
be expected that the shelf life of this material would be less than that of the 
silica coated Fe but again further testing would be required. In order to 
overcome the dipole separation issue, DMSA may be used in conjunction 
with a silica layer to infer greater biocompatibility. However the surface may 
need pre-treatment prior to the addition of any additional surface 
functionalization due to the mix of available surface groups presented by 
DMSA.  
 
5.3.1 Chapter Summary 
These brief investigations have demonstrated some extended 
versatility of the materials developed in this thesis. The successful 
demonstration of the ability to target the Fe@SiO particles to specific sites 
within an animal model is offered greater significance by the materials 
ability to act as a hyperthermia agent. Further study is required in order to 
establish if this material is a viable material for hyperthermia applications. 
However targeted drug delivery may offer greater promise given the materials 
structural properties and lower overall heat transfer rate.  
 The greatly enhanced biocompatibility of DMSA may be used for non-
targeting applications or as a surface layer on a composite material to imbue 
biocompatibility. The surface coating process is simple and can yield large 
amounts of product which is a good advantage for a material heading into 
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any clinical setting. If used as an upper coating on the surface of 
nanoprobes it may require blocking of either the thiol of carboxylic groups to 
enable selective attachment depending on the biomarker binding technique 
used.  
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Chapter 6 
6.1.0 Conclusions and future work 
This chapter will present an overall summary of the findings 
presented throughout the body of this thesis along with a discussion of the 
future work that will be carried out. 
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6.1.1 Conclusions 
The treatment of cancers remains one of the few infuriatingly unsolved 
and poorly understood major health concerns of the Common Era. A host of 
treatments have been developed that enable us to stave off the effects and in 
some cases heal the afflicted, but a great deal more can be done. New 
developments in technology have allowed researchers to manipulate 
materials on unprecedented scales and harness the properties of the 
quantum realm to our ends. With these developments come new materials 
and approaches to old problems including the treatments of cancer.  
Current imaging techniques such as MRI use contrast agents to 
enhance the imaging process used to diagnose and treat cancerous tissues. 
Many of these contrast agents are based on gadolinium which has excellent 
properties, yet is not applicable in all cases and may see greater phase out 
pressure in the future due to toxicity concerns. Iron oxides offer an 
alternative to gadolinium, but have for a long time been limited in its 
application due to particle size constraints. 
The specific aim of this thesis was to demonstrate that iron oxide 
based particles can be produced that not only can operate as functional T2 
contrast agents, but can also specifically target tumorous tissues. It was the 
underlying aim to develop a targeted contrast agent that could be suitably 
applied within clinical settings. This was accomplished using thermal 
decomposition techniques to produce the core magnetite materials which 
were then surface stabilised using a silica coating. Two primary materials 
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were fabricated during the course of this research and were discussed 
separately in chapters 3 and 4.  
The quasi cubic particles presented in chapter 3 served as a trial run 
to first establish the properties of such a material and secondly to examine 
the performance of silica coated magnetite particles as T2 contrast agents. 
This ―Mag@SiO2‖ material proved to be biocompatible and behaved as 
excellent contrast agent in both in vitro and in vivo studies. Despite its good 
performance, it did however lack the small size and particle size distribution 
to prove viable for further studies.  
What we learned from fabricating the Mag@SiO2 particles we applied 
to the production of a smaller more controlled core shell particle which we 
termed Fe@SiO. The particles were less than 60 nm in diameter and 
demonstrated similar biocompatibility and cell uptake compared to that of 
the previous material. The Fe@SiO particles were subsequently modified to 
carry a Herceptin® biomarker which enabled them to specifically target 
cellular uptake by cancerous cells. This was confirmed by comparing uptake 
rates with HER2 surface expression on breast cancer cells which correlated 
well. Finally this material was successfully trailed in vivo as a breast tumour 
specific contrast agent by targeting SKBR3 breast tumours grown in mice 
intravenous tail injection.  
The successfully application as a viable targeted T2 contrast agent, of 
a silica coated magnetite based nanoparticle has been demonstrated. The 
data shows significant darkening at the tumour site 4 and 24 hours post 
injection and a high level of stability and biocompatibility was illustrated 
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through MTS assays and confocal microscopy. This material offers a 
promising platform for targeted MR contrast using silica coated magnetite 
with possible further applications in hyperthermia and drug delivery 
systems. 
 
6.1.2 Future work 
As has been discussed in chapter 5, there are many further 
applications of the materials presented in this thesis. However with 
particular interest, we will be pursuing the development of targeted drug 
delivery platforms based on the core shell materials presented in chapter 4.  
This work will investigate the performance of core/shell magnetite 
nanoparticles coated with drug laden thermoresponsive polymer and 
Herceptin® as a targeted, RF induced release, drug delivery platform. We 
have been fortunate to receive a category 1 research grant in the form of a 
Victorian Postdoctoral Research Fellowship in order to pursue this research 
in collaboration with Prof. Sanjiv Gambhir from the Molecular Imaging 
Program Stanford (MIPS). This research funding will allow two years to be 
spent developing these materials within Prof. Gambhirs group and a third 
year at RMIT University upon returning Australia. 
As many of the nanoparticle factors have already been addressed 
during the course of my PhD investigations, specific attention will be 
focused on optimising the core magnetite materials so that maximum 
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heating potential is gained with minimal loss of beneficial magnetization 
values used for MR contrast.  
Fabrication of outer coatings of thermoresponsive polymer layers and 
subsequent drug loading and release profiles will be the primary focus after 
core optimisation. The targeting capabilities of the particles will be further 
developed under the guidance of world leading researchers in that specific 
topic at MIPS.  
We intend to develop a modular nanoparticle platform that can be 
applied to different applications via changing only the drug carried or the 
attached targeting moiety. Clinical application will remain in the forefront of 
the expectations of the materials, as such all the production methods will be 
developed such that clinical quality and quantity can be produced. 
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